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Abstract of the dissertation 
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by 
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Human Immunodeficiency Virus Type 1 (HIV-1) envelope protein is the sole 
determinant for viral entry and tropism. The ability of HIV-1 to infect susceptible host cells 
depends on the ability of its envelope protein to engage host cell receptor CD4 and coreceptor C-
C Chemokine Receptor Type 5 (CCR5) and/or C-X-C Chemokine Receptor Type 4 (CXCR4). 
Most naturally occurring infections start with a single CCR5-tropic virion. In approximately 50% 
of HIV-1 Clade B infected patients, the viral population spontaneous develops the ability to 
utilize CXCR4 at a late disease stage, and this coreceptor shift corresponds to a poor prognosis 
for the patients. Clinical application of a CCR5 antagonist drug accelerates this coreceptor shift 
process. Despite the important implications of HIV-1 tropism on disease pathogenesis, 
prognosis, and treatment, molecular mechanisms for coreceptor shift and the contributing 
envelope determinants have not yet been clearly defined due to the dynamic, multimeric, multi-
step nature of envelope-coreceptor interaction. In order to better understand the regions on 
envelope that are important for coreceptor specificity, we studied a panel of HIV-1 envelope 
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amplicon samples from patients who experienced coreceptor shift and treatment failure in a 
CCR5 antagonist clinical trial. In order to further understand the structure-function relationship 
of HIV-1 envelope, we utilized both in-depth single clone analysis to fully characterize the 
functional attributes of individual envelope isolates, and high-throughput deep sequencing 
analysis to investigate the global envelope variant landscape before and after treatment. 
In the single clone analysis, we applied both tissue-culture based phenotypic tropism 
characterization, as well as sequence-based genotypic analysis towards 97 single envelope clones 
isolated from four samples of two study subjects. Unique quasispecies composition were found 
post coreceptor shift in two individuals who had different courses of disease. In addition, one 
subject showed drastic sequence variation between isolates from before and after treatment, and 
a highly homogeneous viral population post treatment. This suggested a rapid shift to CXCR4-
using variants that accounted for failure to respond to CCR5 antagonist treatment.  
In the deep sequencing analysis, we developed a novel comprehensive approach to 
sequence a large number of phenotypic validated variants on two next-generation sequencing 
platforms. This approach offered an unprecedented view of the viral quasispecies landscape in 
vivo, as well as on the dynamic population change in response to drug selection.  Regions of 
interest that strongly associated with the usage of CXCR4 coreceptor were identified, including 
previously reported coreceptor specificity sites within and outside V3, the CD4 binding site, and 
gp41-gp120 interaction site within the same protomer and between neighboring protomers in the 
envelope trimer spike. These findings have potentially implications in rational design of better 
coreceptor inhibitors, and development of more accurate predictive algorithms for HIV-1 
envelope tropism. 
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Chapter 1 
Introduction 
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Human Immunodeficiency Virus (HIV) is an enveloped virus that enters into a 
susceptible host cell via a receptor-mediated fusion event between the host cell membrane and 
viral membrane (1-3). Like most enveloped viruses, this receptor binding process is mediated by 
a viral glycoprotein located on the lipid envelope of the virus, such as the envelope protein on 
HIV and the hemagglutinin protein on influenza virus (4, 5). The specificity of viral protein and 
host cell receptor interaction determines the range of host cell types that a virus could potentially 
infect, namely the viral tropism. Viral tropism is critical in disease pathogenesis and progression, 
prognosis, and treatment options. In this chapter, I will introduce some background knowledge 
on HIV virology and pathogenesis, envelope structure and cell entry process, tropism shift and 
its potential therapeutic implications, as well as the current and future tropism testing approaches. 
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1.1 HIV-1 and AIDS  
 HIV is a complex retrovirus and the etiologic agent of acquired immunodeficiency 
syndrome (AIDS) first discovered in 1983. A virion comprises of a nucleocapsid core, where its 
genetic information is stored in two copies of its positive sense single stranded RNA genome, 
and encapsulated by viral matrix proteins and nucleocapsid protein. On the exterior of the 
nucleocapsid core there is a roughly spherical-shaped lipid bilayer membrane called the envelope 
(6). On the lipid bilayer membrane, there are viral envelope proteins forming trimeric spikes that 
can interact with the host cell surface receptor and coreceptors to initiate an infection (7). 
HIV/AIDS remains a major global public health problem today. About 37 million people 
world-wide are living with HIV infection as of the end of 2014. Over 34 million deaths have 
occurred to-date as a result of HIV infection. Each year there are 2 million new infection cases 
and approximately 1.2 million HIV-associated deaths. The pandemic is the most severe in 
regions of sub-Saharan Africa where there is heavy disease burden and poor access to testing and 
treatment (Figure 1.1) (UNAIDS) (8). 
 The term HIV refers to two distantly related viruses, HIV-1 and HIV-2, which were 
independently introduced from their zoonotic origins to humans (9, 10). HIV-1 is more 
pathogenic and responsible the global AIDS epidemic, whereas HIV-2 is less infectious, with 
cases mostly restricted to West African regions, and has a slower progression to full-blown 
AIDS. HIV-1 can be further categorized into Groups including M, N, O, and P, of which Group 
M (main) causes the majority of HIV-1 infection world-wide. Based on sequence diversity, 
Group M is further classified in subtypes A, B, C, D, F, G, H, J, K, and circulating recombinant 
forms (CRFs) (11, 12). The dominant subtype in the Americas and Europe is Subtype B, while 
over half of all HIV cases are caused by Subtype C, which is also the most dominant subtype in 
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Africa. The different subtypes represent rapid evolution of HIV-1 in various geographic areas as 
a direct consequence of its high mutation and recombination rate as well as its high turnover rate 
in the host. 
 The current standard of care for HIV patients is typically a combination of antiretroviral 
drugs in a treatment called highly active antiretroviral therapy (HAART) (13). HAART drugs 
target primarily three viral proteins, protease, reverse transcriptase, and integrase. Current WHO 
recommendation on first time baseline combination includes two nucleoside reverse transcriptase 
inhibitors (NRTI) and one non-nucleoside reverse transcriptase inhibitor (NNRTI), one protease 
inhibitor (PI) or one integrase inhibitor (WHO) (14, 15). HAART can effectively suppress 
circulating viral load, therefore, significantly reducing mobility and mortality of AIDS, but it 
does not provide a cure (16, 17). A drug holiday for one or two weeks can result in a blood viral 
load rebound back to the pre-treatment level (18). Therefore, the treatment has to be taken 
continuously for life. Apart from the public health issues that accessibility to HAART drugs are 
far from universal, taking antiretroviral drugs long term could lead to other complications 
including toxicity and development of drug-resistant strains of HIV (19-21). Taken together, the 
present treatment options for HIV/AIDS are insufficient to address the global AIDS pandemic, 
and more efforts are needed to understand the biology of HIV infection in the hope to provide 
guidelines in future drug and vaccine development processes. 
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1.2 HIV life cycle and pathogenesis 
 A productive HIV-1 infection at the cellular level starts with viral entry (Figure 1.2) (1, 
6). Following attachment to the extracellular matrix or cell surface receptors of a susceptible cell, 
the viral envelop protein engages with a cell surface receptor CD4, undergoes a large 
conformational change, and then engages with its coreceptor, CCR5 or CXCR4 (22, 23). Upon 
coreceptor binding, further conformational changes occur, inserting the fusion peptide into the 
cellular membrane, pulling together the viral membrane and the cellular membrane to a critical 
distance, resulting in hemi-fusion and fusion of the two membranes. After the formation of 
fusion pore, the virion nucleocapsid is transported into the cytoplasm of the infected cells. 
 Once the HIV nucleocapsid core enters the cytoplasm, uncoating occurs and converts the 
nucleoprotein core into the reverse transcription complex (RTC) (24) where reverse transcription 
of the viral RNA genome into a double-stranded DNA copy takes place (25, 26). The RTC is 
then transformed into the pre-integration complex (PIC), chaperoned to the nuclear pore where 
the PIC enters the nucleus for integration. Upon integration, the viral DNA genome becomes part 
of the chromosomal DNA in the infected cell and is called a provirus. Expression of viral RNA 
and proteins are realized through cellular transcription and translation machineries. Newly 
manufactured viral constituents are transported to the plasma membrane of the infected cell, 
where viral assembly and budding occur. The gag-pro-pol polyprotein mediates the assembly 
process by packaging two copies of positive sense single-strand viral genomic RNA into the 
budding virion, recruiting accessory proteins and envelope protein, and generating a spherical 
viral particle. The host endosomal sorting complexes required for transport (ESCRT) system 
releases the particles from the plasma membrane of the infected cells (27). Upon budding, the 
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viral protease cleaves the Gag-Pol polyprotein, resulting in fully processed structural components 
that rearrange to form a mature nucleocapsid core capable of infecting a new host cell (6, 28, 29).  
 At an organismal level, HIV can be transmitted through sexual, percutaneous, and 
perinatal routes. A new infection via mucosal transmission is typically established by a single 
CCR5-tropic founder virus that infects a partially activated memory CD4
+
 T lymphocyte near the 
site of exposure (30). The infected T cell then migrates to a draining lymph node to start a 
peripheral infection, which then quickly proceeds to a systemic infection within weeks. During 
the initial stages of infection, CD4
+
 T cells in gut-associated lymphoid tissues (GALT) are 
massively depleted due to active infection as well as abortive infection induced through by-
stander T cell pyroptosis (31). Cellular, and later, humoral immune responses counteract active 
viral replication and infection but are unable to clear the virus, resulting in a viral load set-point 
that usually is stable throughout the seven to ten years of the clinical latency period. In the later 
phase of infection, especially by the time immunodeficiency starts, the virus has largely depleted 
CCR5-expressing memory T cell compartment, and sometimes evolved to infect CXCR4-
expressing naïve T cells. HIV/AIDS patients, if untreated, usually become so 
immunocompromised that they succumb to multiple severe opportunistic infections that are rare 
and non-life-threatening in immunocompetent individuals (32, 33).  
 A thorough understanding of the HIV viral life cycle and its disease pathogenesis is 
central to the development of intervening methods that block the replication cycle or stop disease 
progression. For example, entry inhibitors prevent the virus from infecting a target cell in the 
first place, thus, such agents could potentially be used in pre-exposure microbiocide creams or as 
post-exposure prophylactics (34). Entry inhibitors also prevent the newly released virus from 
undergo another round of infection, thus, they could be used as one component of the HAART 
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regimen cocktail in combination with other drugs to suppress viral replication in a chronically 
infected patient. 
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 1.3 HIV-1 cell entry and entry inhibitors 
 Viral entry into a susceptible target cell is the first step in the virus replication cycle. The 
entry event might occur at the plasma membrane or within an endocytic compartment of a 
targeted cell in a pH-independent manner (1). Viral entry, mediated by the envelope protein, is a 
dynamic, multimeric, multi-step process that involves several protein-protein interactions, 
consecutive conformational changes, membrane fusion, and the eventual translocation of the 
viral nucleocapsid core (Figure 1.3) (28). Several key steps in the entry process are being 
targeted for the development of entry inhibitors (35-40).  
 During viral attachment, nonspecific interactions with the extracellular heparan sulfate 
proteoglycans, and specific interaction with cell surface proteins DC-SIGN and α4β7 integrin, 
bring the virion to a close proximity with the plasma membrane of a target cell. The viral 
envelope trimeric spike encounters and engages CD4, the primary host receptor required for 
HIV-1 infection (41-43). CD4 is an immune cell surface marker expressed on a subset of T 
lymphocytes (CD4
+
 T cells), dendritic cells (CD4
+
 DCs), and macrophages, all of which are cell 
types susceptible to HIV-1 infection. CD4 binding to gp120 leads to a conformational change 
that forms a bridging sheet, and allows an otherwise buried region including variable loop (V3) 
to be repositioned and exposed, forming a critical contact platform for the subsequent coreceptor 
interaction step (44).  
  Human chemokine receptors, CCR5 and CXCR4, are the two major coreceptors playing 
significant roles in viral entry in vivo. Both CCR5 and CXCR4 are G-protein coupled seven-
transmembrane receptors that are expressed on a variety of cell types including certain immune 
cell subsets. In a normal immunological context, interaction between chemoattractant cytokines 
and their receptors interact and modulate immune cell migration and sometimes influx into sites 
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of injury and inflammation. CXCR4 is widely and constitutively expressed on many cell types, 
including thymocytes and naïve T cells that require CXCR4-CXCL12 interaction for 
development and homeostasis (45). In a pathological context, CXCR4 also plays an important 
role in cancer cell survival and metastasis. On the other hand, CCR5 has a narrower expression 
profile including activated and memory T cells. CCR5 interacts with its ligands MIP1, MIP1 
and RANTES for T cell costimulation and inflammatory immune responses, though it appears to 
be dispensable, with no severe immunodeficiency in people carrying homozygous null alleles 
(46).  
 The process of envelope-coreceptor interaction is not clearly defined but is thought to 
occur according to a two-site model. Site one is the amino-terminus of a coreceptor that interacts 
with the base of V3 loop, and site two is the extracellular loops of a coreceptor that interacts with 
the now exposed V3 region on gp120 upon CD4 binding (47, 48). As the coreceptors fully 
engage gp120, further conformational changes allow the hydrophobic gp41 fusion peptide to 
inserts into the host membrane, while the transmembrane domain of gp41 still anchors its 
carboxyl terminus in the viral membrane. As a Class I fusion machinery, two heptad repeat (HR) 
regions in gp41, HR1 and HR2, fall back on each other in antiparallel orientation, forming a 
coiled-coil six-helical bundle that pulls together the viral and host membrane to a proximity close 
enough for mixing of the outer leaflet of the two membranes, and eventual formation of a fusion 
pore (49-52). The viral nucleocapsid is then translocated through the pore into the host cell 
cytoplasm. 
 A number of therapeutic developments focus on blocking different steps in the entry 
process, such as CD4 binding, coreceptor binding, and fusion (34, 53, 54). For example, vaccine 
engineering research focuses on broadly neutralizing antibodies that target native envelope 
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trimers in an attempt to block viral attachment or entry (55-60). Small molecules and monoclonal 
antibodies are tested for their ability to target CD4 or the CD4 binding site on gp120 (61-63). 
Fusion inhibitors include Enfuvertide (Fuzeon, Roche), which is a 36-amino-acid-long HR2-
based peptide that competes with HR2 and binds to HR1 in gp41 region , therefore preventing 
the formation of the six-helical bundle and stopping fusion (64-70). With the discovery of a rare, 
naturally occurring, protective loss-of-function CCR532 mutation, blocking or removing CCR5 
from the host cell became an attractive strategy (71, 72). Small molecule antagonists and gene 
therapy agents such as Zinc finger nucleases (ZFN) have been studied in the laboratories and in 
clinical trials (73-78). Maraviroc (MRV), a small molecular CCR5 antagonist, is the only 
coreceptor inhibitor approved by Food and Drug Administration (FDA) as a second line 
treatment for patients who have exhausted first line options (48, 79-83). Inhibitors to CXCR4 
were developed but not approved for long-term HIV treatment due to its adverse effects. Single 
dose administration of AMD3100 (Mozobil or Plerixafor), a potent CXCR4 inhibitor, is 
approved to be used in bone marrow donors to mobilize bone-marrow residing hematopoietic 
stem cells before transplant but is not used for HIV-1 treatment due to side effects (84, 85).  
Overall, HIV-1 viral entry is a multi-step process that remains an attractive target for 
active development of entry inhibitors (86-88). Although a number of small molecule drugs and 
biologics are being studied in clinical trials, only two were FDA approved to be used as second 
line HIV drugs. More effort to understand the molecular details between HIV-1 envelope and 
coreceptor interaction during cell entry can provide valuable guideline for the future 
development of efficacious, precisely-targeting therapeutic agents. 
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1.4 Envelope structure and tropism determinants 
The native HIV-1 envelope protein exists as a trimer of gp120-gp41 heterodimers on the 
viral membrane. The full-length envelope precursor protein gp160 is cleaved into a 
transmembrane subunit called gp41 and a surface subunit called gp120 (89). The two subunits 
are non-covalently attached, and form a trimer of heterodimers on the viral lipid membrane, 
called an envelope trimer spike (90). Based on structural studies and models, one HIV-1 virion 
has approximately 14 envelope spikes, on average, on its lipid membrane, which is a very low 
number compared to other enveloped viruses, such as influenza and dengue viruses (7, 91). The 
sparse location of envelope spikes on a virion is thought to minimize crosslinking of B cell 
receptor and elicitation of a humoral immune response (92). In addition, gp120 is heavily 
glycosylated with over 20 glycosylation sites (93). The glycan shield on the exterior of the 
envelope spike also helps to evade the neutralizing antibody response (94, 95). 
HIV-1 gp120 can be further divided into five relatively conserved regions (C1 through 
C5) that form the gp120 core, interspersed by five variable regions (V1 through V5) that are 
mostly located at or near the outer surface of gp120 to shield the more conserved inner core from 
the immune system (Figure 1.4) (96-99). Disulfide bridges link the two cysteine residues at the 
base of each variable loop except for V5. The variable loops are named due to their sequence 
hyper-variability among different envelope isolates. Among the five variable loops, the V3 loop 
is much less variable than V1/2 and V4, especially in terms of insertions and deletions (44).  
The V3 loop has been extensively studied for its critical role in coreceptor binding 
(Figure 1.5) (96). Sub-regions in V3 have been shown to be conserved, especially in CCR5-using 
viruses (R5 viruses), highlighting the possibility that V3 interacts directly with CCR5 with some 
degree of structural stringency. On the other hand, the V3 sequences in CXCR4-using viruses 
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(X4 viruses) are more diverse. Currently, a plethora of mutagenesis and structural studies support 
the theory of a CCR5 amino-terminal interaction with the base of V3, in particular a sulphated 
tyrosine at Position 10 of CCR5 forming a salt bridge interaction with a highly conserved 
arginine at Position 327 of gp120. Computational docking simulations also demonstrated a 
possible interaction between the CCR5 amino-terminus with the CD4-bound gp120 structure. 
However, there is no direct crystallographic evidence or molecular details of the direct 
interaction between the V3 loop and CCR5 or CXCR4 extracellular domains.  
Besides being a critical piece in coreceptor binding, the V3 loop is also the principal 
determinant in coreceptor specificity (100, 101). The functional capacity of gp120 to interact 
with CCR5 and/or CXCR4 bears clinical significance in treatment options and disease prognosis. 
Studies show that in an artificial pseudotyping system, exchanging the V3 loops between CCR5-
tropic and CXCR4-tropic envelope strains can result in a switch in tropism, demonstrating the 
importance of V3 in coreceptor choice (102). However, in vivo envelope mutation and evolution 
in a physiological context is more complex. For example, the 11/25 Rule states that positively 
charged residues on the V3 loop in particular at Position 11 and 25, as well as the net positive 
charge of V3, are strongly associated with CXCR4 usage.  
 A large body of literature has focused on the V3 loop, as it is the principal determinant of 
HIV-1 tropism (103-107). However, HIV-1 envelop also modulates its interaction with the 
coreceptor via regions outside the V3 loop (108-112). Covariance of a negatively charged amino 
acid at Position 440 in C4 region and a positively charged residue at Position 322 in V3 were 
shown to associate with strong with R5-using Subtype B virus; incorporating the status of 
Position 440 could improve the predictive power of existing tropism predictive algorithms. 
Mutations in gp41 correlate highly with X4-usage and are validated in patients in MRV clinical 
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trials (113). Biochemical and biophysical analysis also showed that residues that influence 
tropism are identified in V1, V2, C4, and gp41 regions (114). In particular, the tropism-
determining residues of gp41 likely influence gp120-coreceptor interaction via modulating 
binding affinity and complex stability (115). Since the envelope-coreceptor interaction is a 
multimeric, highly dynamic process, residues that are not located at the contact surface might 
still influence the tropism indirectly by stabilizing or destabilizing the interaction with a 
coreceptor (116). A more thorough and nuanced understanding of gp120-gp41-CD4-coreceptor 
interaction, including the role of V3 and determinants outside V3, would potentially improve 
tropism predictive algorithms and reveal new drug targets (117). 
  
  
14 
 
1.5 HIV-1 quasispecies and coreceptor shift 
 HIV-1 exists in patients not as a homogenous clone of virus with identical genomes, but 
as a quasispecies, or a group of related but non-identical variants. This population of variants is a 
result of high levels of viral replication soon after the initial infection (118). As previously 
mentioned, a new infection usually starts from a single R5-tropic transmitter / founder virus. 
Upon establishment of a productive infection, rapid replication occurs, with mutations and 
recombination accumulating, and selected along the way for improved fitness in the host. The 
error-prone viral reverse transcriptase, in combination with rapid viral reproduction, results in an 
estimated mutation rate that allows changes at every single nucleotide position in the viral 
genome within a day (119-122). Therefore, a viral quasispecies population in the host is 
adaptable to various selection pressures coming from the host immune system or from 
antiretroviral therapies (123). The HAART regimen was developed based on this understanding, 
that the virus can quickly become resistant to any mono-therapy, but it is less likely to gain 
resistance to multiple drugs administered simultaneously.  
 In the context of tropism, at the early stage of HIV-1 infection, CCR5-tropic virus 
predominates largely over the asymptomatic period, probably reflecting a bottleneck event in the 
transmission process. As the CCR5-expressing T cells are depleted, selection pressure drives the 
quasispecies to utilize the alternative coreceptor CXCR4 and in the presence of less CD4 
expression. Current nomenclature broadly categorizes HIV-1 isolates into CCR5-tropic (R5), 
CXCR4-tropic (X4), and CCR5/CXCR4-tropic (dual or R5X4) clones. In reality, however, 
strictly R5-tropism and strictly X4-tropism are the opposite ends of a spectrum, where most 
physiological variants fall on the spectrum in between the two ends. Strictly X4-tropic variants 
are rare, as most infections start with a R5-tropic virus and evolve towards different levels of 
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capacity in using CXCR4. Approximately 50% of HIV-1 Clade B patients spontaneously 
develop X4-using viruses in the later stage of infection, and the presence of X4-using virus 
(including dual-tropic and X4-tropic) correlates with a worse clinical prognosis (124). It is 
unclear whether the emergence of X4-using virus is the cause or result of a more severe disease. 
 Some patients receiving CCR5 antagonist therapy experience an expedited course of X4-
using virus emergence and become unresponsive to the coreceptor inhibitor treatment (Figure 
1.6). This could lead to treatment failure and viral load rebound. The conversion from R5-
tropism to dual- or X4-tropism is called coreceptor shift. Again it is unclear if this presence of 
X4-using virus will cause worse disease outcome, or whether it is the result of disease 
progression. In some of the individuals who undergo coreceptor shift, the viral tropism reverts 
back to R5 upon withdrawal of the CCR5 antagonist therapy, reflecting the adaptability of the 
quasispecies population in response to external selection pressures, as well as a potential fitness 
cost in X4-usage (125). 
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1.6 Phenotypic tropism testing 
 The current gold standard for viral tropism determination is tissue-culture based 
phenotypic tests, such as the Enhanced Sensitivity Trofile Assay (ESTA) (126-128). The 
phenotypic testing is usually performed by pseudotyping patient-derived gp160 coding sequence 
on infectious particles, and infecting cell lines expressing CD4 and CCR5 or CXCR4 using these 
pseudotyped viruses. The infection outcome is detected with a reporter system such as 
fluorescence or luminescence. The advantage of a phenotypically based assay is that it is highly 
accurate, sensitive, and includes all tropism determinants on the full-length gp160 envelope 
region. The ESTA reports 100% sensitivity at detecting 0.3% X4-using minor variant at a 
starting viral load larger than or equal to 1000 copies per milliliter of blood. The disadvantages 
of a phenotypic assay include high cost, long turn-around time, sometimes inconclusive results, 
and being labor-intensive. Since clinical administration of a CCR5 antagonist requires prior 
tropism determination that the patient does not harbor X4-using variants, such drawbacks of the 
phenotypic tropism testing directly limit the application of the CCR5 antagonist drug.  
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1.7 Genotypic tropism testing 
 With the impressive advancement of the next-generation-sequencing (NGS) technology 
over the past decade, genotypic analysis of HIV-1 quasispecies becomes feasible (129-136). 
NGS technology was developed to meet the demand for higher-throughput, cheaper sequencing 
methods in the Human Genome Project, and has become increasingly useful in the study of 
microbial communities called the microbiome. The ability to produce sequencing libraries in a 
cell-free system without cloning, the massive parallelization of sequencing reactions from the 
advancement of microfluidics technology, and the real-time base-interrogation technology 
without the need for electrophoresis, allow millions and billions of sequencing reads to be 
produced in one run (137). The unprecedented scale and speed of NGS opened doors for 
genomic and genotypic approaches in disease diagnosis and testing, including HIV-1 tropism 
testing. 
Illumina sequencing technology is the most widely used mainstream NGS platform today. 
It has different sequencing systems developed for different applications based on genome size 
and output volume. The MiSeq system is designed to sequence small genomes, amplicons or 
targeted gene panels with a fast turnaround time (within 6 hours), ideal for genotypic 
determination in clinical laboratories (138). The basic workflow of Illumina NGS system 
includes fragmentation of input DNA into several hundred base-pairs, ligation of an adaptor on 
both ends of the fragments, immobilization of the adaptor-DNA fragment on a flow cell, solid-
phage bridge amplification to produce millions of densely packed clusters, and sequencing by 
synthesis using labelled nucleotide terminators (Figure 1.7). Each cluster comes from one DNA 
fragment in the input sample, and will produce one read after sequencing. A CCD camera is used 
to capture fluorescence as each terminator base is being added to the growing DNA polymer, and 
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the output reads are typically 50 – 250 nucleotides in length, depending on the sequencer and 
customized settings.  The advantage of Illumina sequencing lies in its massive amount of output, 
ranging from millions to billions of reads per run. This allows hundreds to tens of thousands 
folds of coverage for a small genome or an amplicon gene. It is ideal to uncover rare variants that 
comprises of less than 1% of the input population, for example in a patient-derived HIV-1 
envelope amplicon sample where the majority of the variants are R5-tropic but minor X4-tropic 
variants exist at a low percentage (139-142). The challenge for genotypic testing by Illumina 
sequencing comes from the need to reconstruct short reads into a longer haplotype. It is difficult 
to analyze mutations that are longer than the length of the reads, as the linkage information 
would be lost over the fragmentation and sequencing process. 
In order to address the issues brought about by the short read length in Illumina 
technology, several new cutting-edge “third-generation sequencing” technologies that focuses on 
longer sequence of single DNA molecules emerged. I will still call them next-generation 
sequencing for the sake of simplicity. Pacific Biosciences (PB) single-molecule, real-time 
(SMRT) sequencing is one of them (Figure 1.8) (143, 144). Some breakthroughs for the PB 
sequencing technology include (1) utilization of zero-mode waveguides that are small wells on a 
SMRT cell to house single DNA molecule, therefore blocking light from other sequencing 
reactions and reduce background noise; a novel DNA polymerase and sequencing chemistry that 
can generate long reads up to tens of kilobases in length; and (3) sequencing in a circular fashion 
to allow multiple passes on the input DNA fragment on both strands, therefore resulting in a 
circular consensus sequence (CCS) for each single molecule sequenced and reducing error rate. 
Comparing to Illumina platforms, PB sequencing generates fewer reads in the range of thousands 
to tens of thousands, therefore the coverage is not as high but still more than sufficient in 
  
19 
 
analysis of a small genome or amplicon. In the context of genotypic testing for HIV-1 tropism, 
the added advantage of PB sequencing is that mutation located at different domains of the 
envelope gene can be correlated thanks to the long CCS reads. It affords analysis of covariance 
between different loci and allows better understanding of structure-function relationship of the 
envelope. 
Since the NGS-based genotypic assays routinely multiplex samples to maximize the 
utilization of its massive sequencing capacity, development of high-throughput low-cost 
genotypic testing methods is a possibility. With a deep coverage and robust analysis pipeline, it 
is possible to detect minor variants at a comparable or higher sensitivity than the current ESTA 
approach (146-149). The limit of detection of NGS-based genotypic assay is based on the level 
of noise, namely the intrinsic combined error rate of the sample preparation procedures and the 
sequencing chemistry, which hopefully decreases as the NGS technology advances. Due to its 
incredible depth of coverage, NGS-based genotypic testing offers a more detailed, high 
resolution picture of quasispecies landscape in patients, allowing doctors to make more informed 
decisions (150). In addition, a NGS-based genotypic assay could potential sequence the entire 
genome of HIV-1, and detect mutations that confer resistance in multiple viral targets across 
different classes of antiretroviral drugs in an all-inclusive multiplex style (151), providing a one-
stop complete diagnostic and monitoring assay for HIV patient management. 
  Major disadvantages of the NGS-based genotypic testing include bioinformatic 
challenges in data analysis, and prior knowledge of structure-function relationship in result 
interpretation (152). In HIV-1 genotypic tropism determination, the latter is especially 
challenging, given that the envelope sequence is so variable, and we do not understand all 
tropism determinants in gp160 sequence. Currently available computational algorithms, 
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Geno2Pheno[coreceptor] and Web PSSM, are designed to make tropism predictions based on the 
V3 loop sequence, the major but not only determinant for tropism (153-159). These algorithms 
are trained on a limited set of Subtype B sequences that only accounts for 10% of the global 
circulating strains, and are not as accurate in other subtypes that account for the majority of HIV-
1 infections worldwide (160, 161). In addition, even for Subtype B V3 sequences, the algorithms 
achieve high specificity (few false positives) but low to moderate sensitivity (many false 
negatives) at predicting X4-using variants (162). The current US and European guidelines for 
MRV administration based on genotypic testing results predicted by Geno2Pheno[coreceptor] 
recommend a false positive rate cut off that ranges from 2 – 5.75% based on MOTIVATE trial 
data, up to 10%, highlighting the inadequacy of the current predictive algorithms (163-165). One 
potential way to improve the predictive power is to incorporate other non-V3 determinants that 
differentiate X4-using variants into the algorithms (166). This requires more research to 
understand the structure-function relationship of HIV-1 envelope in the context of coreceptor 
binding and specificity. A streamlined, optimized genotypic assay would ideally be high-
throughput, fast-turnaround, low cost, and highly specific and sensitive, so more patients eligible 
for MRV and other future coreceptor inhibitors could benefit from the respective therapy.  
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1.8 Conclusion 
 Over the past three decades, we have come a long way in understanding HIV biology, 
designing optimized treatment methods, and alleviating the morbidity and mortality associated 
with the disease. However, HIV/AIDS remain a public health priority today, with 2 million new 
cases each year, increasing prevalence of drug-resistant strains, and lack of access to testing and 
treatment. The current HAART drugs can effectively suppress viral load and pathology but do 
not provide a cure. As a result, HIV patients need to take HAART therapy for the rest of their 
lives, raising concerns with long term toxicity and resistance development. Therefore, there is a 
continuous need for development of new treatment options and vaccines. Coreceptor inhibitors 
are a new class of drugs that could potentially benefit patients if administered properly. Further 
understanding of HIV-1 envelope protein interaction with coreceptors could shed light on future 
inhibitor design and tropism predictive algorithm improvement.  
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1.9 Figures 
Figure 1.9.1  Adults and children estimated to be living with HIV by the end of 2014. 
 
An estimated 37 million people are living with HIV worldwide. Approximately 70% of all 
people infected with HIV reside in Sub-Saharan Africa.  
 
This figure is adapted from UNAIDS Core Epidemiology Slides (July 2015). 
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Figure 1.9.2  HIV-1 replication cycle. 
 
A range of host cell proteins play a role as restriction factors or dependency factors in the process 
of HIV life cycle. Different steps in the life cycle are numbered as the following: (1) attachment 
and binding to cell surface receptors CD4 and CCR5 or CXCR4; (2) viral fusion and 
translocation of viral nucleocapsid into host cell cytoplasm; (3) uncoating of viral nucleocapsid; 
(4) formation of reverse transcription complex and reverse transcription; (5) formation of pre-
integration complex (PIC) and nuclear import of PIC through nuclear pore; (6) integration of 
pro-viral genome into host cell genome; (7) transcription from the provirus to make viral 
genomic RNA and mRNA; (8) nuclear export of viral genomic RNA and mRNA; (9) translation 
of viral mRNA into accessory proteins and structural proteins (gag-pol); (10) assembly of viral 
RNA genome and gag-pol on the cell plasma membrane; (167) budding of new virions on the 
cell plasma membrane; (12) release of new virions from infected cell membrane via ESCRT 
machinery; and (13) maturation of newly release virion into infectious particles via proteolytic 
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cleave and rearrangement to form a viral nucleocapsid core. Each of the above steps can be 
targeted for intervention. White and blue boxes indicate therapeutic inhibition and cellular 
restriction. INSTI, integrase strand transfer inhibitor; LTR, long terminal repeat; NNRTI, non-
nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor. 
 
This figure is adapted from Alan Engelman and Peter Cherepanov, Nature Reviews 
Microbiology 10, 279-290 (April 2012) 
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Figure 1.9.3  The multi-step HIV entry process mediated by envelope protein. 
 
The HIV-1 envelope protein in native trimer form (left) is shown with gp41 transmembrane 
subunit (blue) and gp120 surface subunit (red). Variable loop regions on gp120 are shown in 
yellow and orange. Upon gp120 engagement with CD4 (green) on cell membrane, the variable 
loops change conformation, exposing the contact site for the subsequent interaction with 
coreceptor CCR5 or CXCR4 (navy). Coreceptor binding results in the insertion of gp41 fusion 
peptide (brown) into the cell membrane, which eventually leads to six-helix bundle formation 
and membrane fusion (right). Therapeutic and research agents that inhibit the above-mentioned 
processes are shown below each step. Ibalizumab (TNX-355) is a monoclonal CD4 antibody that 
binds to CD4 and blocks CD4 binding. Maraviroc, Vicriviroc, and TAK779 are CCR5 
antagonists that bind to CCR5 and blocks coreceptor interaction. AMD3100 is a CXCR4 
inhibitor that blocks CXCR4-tropic viral entry. Enfuvertide (T-20) is a peptide drug that 
competitively blocks the formation of six-helix bundle and prevents membrane fusion. 
This figure is adapted from Bridgette J. Connell and Hugues Lortat-Jacob, Front. Immunol.(20 
November 2013)  
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Figure 1.9.4 Envelope gp120 structure and the V3 loop 
 
(A) Schematic representation of HIV-1 envelope gp120, with V3 crystal structure underneath. 
The envelope surface subunit gp120 is shown in its primary structure, and annotated with its 
conserved regions C1-C5, and variable regions V1-V5. Glycosylation sites are represented as 
branches on the primary structure. V3 loop crystal structure for isolate JR-FL is shown in 
electron density map. Two cysteine residues C396 and C331 linked by disulphide bridge form 
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the base of the V3 loop. The 11
th
 and 25
th
 position on the V3 stem, known to associate with 
coreceptor specificity, are annotated as S306 and E322 respectively. The tip of V3 contains a 
GPGR motif, annotated by P313 and G314.  
(B) Alignment of HIV-1 envelope isolates V3 sequences. The tropism of each V3 loops is 
annotated on the side. Conserved residues are shown in red, including the starting and ending 
cysteine, as well as the GPGR motif at the tip. Position 11 and 25 are annotated.  
 
This figure is adapted from Tilton JC, Doms RW, Antiviral Res., 2010, Huang C. et al, Science, 
2005, and Tan Q et al., Science, 2013. 
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Figure 1.9.5  Computational models of HIV-1 envelope-coreceptor interaction. 
 
(A) HIV-1 envelope trimer binding to host cell surface CD4 and coreceptor CXCR4. The 
interaction is a multi-subunit conglomerate, with the stoichiometry of gp120, CD4, and 
coreceptors not yet clearly defined. Envelope and CD4 are shown as electron density map, while 
CXCR4 is shown in cartoon format. The parts are colored as the following: gp120, teal; CD4, 
gold; CXCR4, navy. The V3 loops from gp120 are colored red, and the contact residues on 
CXCR4 are colored orange.  
(B) CCR5-tropic V3 loop (R5-V3) and CXCR4-tropic V3 loop (X4-V3) interaction with CCR5 
and CXCR4 extracellular domains respectively are shown superimposed. The V3 loop backbone 
makes hydrogen bond with the backbone of extracellular loop 2 (ECL2), while the Proline313 at 
the GPGR motif at the tip of V3 makes hydrophobic interaction with the helices of the 
coreceptors. The parts are colored as the following: R5-V3, pink; X4-V3, yellow; CCR5, blue; 
CXCR4, green.  
 
This figure is adapted from Wang B et al., Science, 2010, and Tan Q et al., Science, 2013.  
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Figure 1.9.6 Drug resistance development process in a quasispecies population. 
 
 
In the context of tropism shift and resistance to coreceptor inhibitors, the starting founder virus 
has a R5-topic wildtype phenotype. Upon selection with R5 inhibitors, resistant variants 
preferentially expand into the majority of the quasispecies population. Upon therapy withdrawal, 
the quasispecies population may demonstrate a reversion into the original R5-topic variants.  
 
This figure is adapted from Kuritzkes DR, PRN, 2004. 
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Figure 1.9.7  Illumina next-generation sequencing (NGS) technology work flow. 
 
 
The steps of Illumina NGS sequencing is the following: (1) random fragmentation of intake 
DNA samples, and ligation of adaptor to both ends of the fragments; (2) immobilization of single 
stranded adaptor-DNA fragment to the flow cell surface; (3) Solid-phase bridge amplification 
using unlabeled nucleotides; (4) formation of several million dense clusters of double-stranded 
DNA from Step (3); (5) addition of labeled terminators, primers, and DNA polymerase to start 
sequencing cycles. (6) captures of emitted fluorescence from each cluster upon laser excitation as 
the DNA elongates; (7) Repeat of Step (5) and (6) to determine the sequence in the DNA 
fragment, one base at a time; and (8) Sequences of input DNA fragments as short reads to be 
mapped onto a reference sequence for analysis. 
This figure is adapted from www.illumina.com  
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Figure 1.9.8 Pacific Biosciences third-generation sequencing technology work flow. 
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(A) Generation of circular consensus sequences (145) on single DNA molecules. Adaptors 
(SMRTbells) are ligated on both ends of double-stranded DNA fragments. Upon denaturation, a 
single-stranded circular DNA is obtained for sequencing, DNA polymerase can sequence the 
circle multiple passes to generate a consensus sequence of high quality.  
(B) SMRT cells for PB system contains zero-mode waveguides (ZMW) that houses single DNA 
molecules during sequencing reaction. The DNA polymerase incorporates labeled nucleotides, 
and the fluorescence from each ZMW are captured and processed into a DNA sequence (trace).  
 
This figure is adapted from Fichot EB and Norman RS, Microbiome 2013, and 
http://www.pacb.com/.  
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Chapter 2 
Single Clone Analysis of HIV-1 Envelope Quasispecies  
Reveals Dynamic Intra-Subject Evolution  
with CCR5 Antagonist Therapy 
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2.1 Preface 
 Chapter 2 is adapted from a manuscript prepared for submission. The author 
contributions are the following: Lee Ratner and Jie Zhang conceived all the experiments; Jie 
Zhang independently performed all the experiments, analyzed all the data, and prepared all the 
tables and figures except for Figure 2.11.4(C) and Figure 2.11.7, which are prepared with help 
from Xiang Gao; Timothy Henrich
 
and Daniel Kuritzkes
 
kindly provided the clinical samples 
used in this study. The manuscript was written and revised by primarily by Jie Zhang and Lee 
Ratner. 
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2.2 Abstract 
HIV-1 envelope interacts with coreceptors CCR5 and/or CXCR4 before gaining entry 
into the host cells through a dynamic, multi-step process.  The tropism determinants on the 
envelope protein are not clearly defined despite recent advances in structural understanding of 
the coreceptors as well as the HIV-1 native envelope trimer spike.  CCR5 inhibitor treatment in 
patients harboring CCR5-tropic virus frequently leads to coreceptor shift and the emergence of 
CXCR4-using virus.  In order to understand the evolutionary pathways of coreceptor shift, we 
examined a panel of single clones from patients before and after they failed CCR5 antagonist 
therapy, using a combination of tissue-culture based phenotypic tropism assays and sequencing-
based genotypic analysis. We found distinct quasispecies compositions in two study subjects 
after the treatment failure. In one of the two subjects, we observed a rapid, complete shift of 
tropism and large variations in the envelope variable regions within a two-week period of drug 
selection. This study reveals the rapid nature of HIV-1 envelope evolution in vivo, and confirms 
key structure-function relationships in envelope coreceptor specificity. 
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2.3 Importance 
Preventing resistance development to current and future antiretroviral therapeutic agents 
is a top priority for global public health against HIV/AIDS. Utilizing a combination of 
phenotypic and genotypic assays on 97 single clones isolated from 2 subjects, we confirmed the 
previously reported sequence signature for CXCR4 tropism, and cross-validated the structure-
function relationship of existing tropism prediction algorithms. In addition, we demonstrated the 
rapid and complete nature of coreceptor shift and treatment escape in one patient, and a slow and 
incomplete coreceptor shift in the other patient, under the specific selection pressure of a CCR5 
antagonist. This finding suggests different evolutionary pathways about coreceptor shift, and has 
implications in clinical administration of coreceptor inhibitors and the need to closely monitor 
quasispecies tropism under such therapy. 
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2.4 Introduction 
 C-C chemokine receptor type 5 (CCR5) and C-X-C chemokine receptor type 4 (CXCR4) 
are host cell targets for small molecule inhibitors against HIV-1 infection (1-3).  After engaging 
the primary receptor CD4, HIV virions can utilize either CCR5 (R5), CXCR4 (X4), or both (dual 
or R5X4) coreceptors to enter a susceptible cell (4, 5). Blocking virion-coreceptor interaction 
stops an infection at the first step of viral replication cycle. Currently, Maraviroc (MRV) is the 
first and only FDA approved small molecule CCR5 antagonist against HIV-1 infection, though a 
number of other small molecules have been developed and tested as coreceptor inhibitors to both 
CCR5 and CXCR4 (6-12). Eligibility for clinical application of MRV requires that a patient 
harbors undetectable X4-tropic virus at the commencement of treatment, typically determined by 
a tissue-culture based phenotypic method called Enhanced Sensitivity Trofile Assay (ESTA) (13). 
Despite the stringent admission criteria, resistance to MRV has been shown to develop in vivo 
through multiple potential mechanisms, such as coreceptor shift from R5- to X4-tropism, and 
binding to different CCR5 confirmations including the coreceptor-drug complex (14-18). 
Resistance development to CCR5 antagonists increases the risk of treatment failure and hampers 
the utilization of current and future coreceptor antagonist therapeutic agents (19). 
 One important factor in the development of resistance to antiretroviral agents lies in the 
fact that HIV-1 exists in the host as quasispecies, or a group of genetically related but non-
identical variants (20). An infection typically starts with a few if not a single 
transmission/founder virus crossing the mucosal barrier, mostly likely a R5 isolate, and 
expansion to more than 10
6
 copies per milliliter of blood a few weeks after infection. During this 
rapid course of replication, the virus accumulates mutations as a result of its error-prone RNA 
polymerase and high turnover rate, and evolves into a community of quasispecies that is 
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adaptable to host and external selection pressures (21). With the memory T lymphocytes being 
depleted over the course of the infection, fifty percent of HIV-1 Clade B patients spontaneously 
develop X4-tropic virus late in the disease course to more efficiently infect naïve T cells and 
bypass inhibitory chemokines produced by HIV-specific cytotoxic T lymphocytes (22). 
Administration of a CCR5 antagonist often expedites the coreceptor shift process (23). In some 
cases, the development of resistance to a CCR5 antagonist occurred at the cost of reduced viral 
fitness, as shown by observed reversion to pre-treatment strains upon the withdrawal of therapy 
(24-28).  An understanding of the mechanism of coreceptor shift will guide rational design of 
better coreceptor inhibitors by blocking the potential paths to resistance development.  
 Despite recent advances in our understanding of HIV-1 envelope trimer structure and the 
structures of both coreceptors through high-resolution crystallography studies, details of 
molecular interactions between the envelope and coreceptors remain to be defined (29-35). 
Numerous studies have shown that the Variable loop 3 (V3) region of HIV-1 envelope is critical 
in coreceptor specificity by making direct contact with extracellular loops of the coreceptors (36-
38).  Regions outside V3, including the C2-V5 regions, that have been shown to regulate 
coreceptor tropism include specific residues at position 440 in C4, and regions in gp41 (Chapter 
3) (39-42). Study of coreceptor antagonist resistant variants allows us to identify key envelope 
determinants for resistance development and coreceptor shift, especially in the context of a 
defined selection pressure (17, 43-47). 
 To better understand the evolutionary process of HIV-1 envelope quasispecies that led to 
drug resistance and coreceptor shift in vivo under the selection of a CCR5 antagonist, we 
analyzed a panel of 97 HIV-1 envelope single clones from 4 samples from 2 subjects who 
experienced treatment failure in a clinical trial for a CCR5 antagonist Vicriviroc (VCV). Using a 
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combination of phenotypic tropism assays and genotypic analysis, we showed a rapid change of 
tropism upon VCV treatment and detected signature changes in envelope V3 regions that 
correspond to the phenotypic coreceptor shift.  
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2.5 Materials and Methods 
2.5.1 Patient samples 
HIV-1 envelope amplicons were obtained from participants in a Vicriviroc (VCV) Phase 
II clinical trial (AIDS Clinical Trials Group [ACTG] A5211; NCT00082498) (48). Participant 
selection and sample preparation were described previously (Manuscript Zhang et al) (49). 
Plasma samples were collected from study participants who experienced virologic failure and 
had tropism change by the phenotypic Trofile assay (Monogram Biosciences). Pelleted virion 
RNA was used to prepared env cDNA. Envelope amplicons were generated using previously 
reported primers (50):  
Env1Atopo (5’-CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-3’)  
FLenv2.2 (5’-AGCTGGATCCGTCTCGAGATACTGCTCCCACCC-3’)  
 
2.5.2 Single Clone Isolation 
Patient envelope amplicons were cloned into expression vectors in frame. Two 
approaches were taken to generate single clones from patient samples. The first approach cloned 
patient envelope amplicon PCR products into pcDNA3.3-TOPO, a TA cloning vector containing 
a CMV promoter, by following the  manufacturer’s protocol (Thermal Fisher Scientific).  The 
TA ligation reaction was prepared using QiaQuick PCR purification columns following the 
manufacturer’s protocol (Qiagen) and electroporated into ElectroMAX Stbl4 competent cells 
(Thermo Fisher) in 1 mm cuvette at 1.2 kV, 25 µF, 200 Ω mA on BioRad MicroPulser (BioRad). 
Transformants were recovered in 1 mL of S.O.C. medium by shaking at 30 °C for 90 minutes at 
225 RPM, and 20 – 100 L was plated on Luria-Broth (LB) agar plates supplemented with 150 
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g/mL of ampicillin (Sigma-Aldrich). Single colonies were separately transferred and grown in 3 
mL of LB liquid media containing 150 g/mL of ampicillin (Sigma-Aldrich) by shaking at 30 °C 
at 225 RPM for 18 – 20 hours.  The resultant culture was used to prepare plasmid DNA using 
PureLink Quick Plasmid Miniprep Kit (Thermal Fisher Scientific).  The single clone plasmids 
were screened for the presence or absence of the insert patient envelope gene and for the 
orientation of the insert using PCR using the following combinations of directional primers.   
CMV-forward: 5’-CGCAAATGGGCGGTAGGCGTG-3’ 
TK polyA-reverse: 5΄-CTTCCGTGTTTCAGTTAGC-3΄ 
Env1Atopo-forward: 5’-CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-3’ 
FL-Env2.2-reverse: 5’-AGCTGGATCCGTCTCGAGATACTGCTCCCACCC-3’ 
A 3kb product with CMV-forward and TK polyA-reverse, and Env1Atopo-forward and FL-
Env2.2-reverse primers confirmed the presence of HIV-1 envelope amplicon insert in pcDNA3.3 
vector. A 3kb product with CMV-forward and FL-Env2.2-reverse primers confirmed that the 
envelope gene is inserted in the forward orientation downstream of the CMV promoter, whereas 
products with TK polyA-reverse and FL-Env2.2-reverse indicated a reverse orientation, 
unsuitable for follow-up expression experiments.  Only pcDNA3.3-TOPO-CMV-Env clones 
containing an envelope gene insert in the correct orientation were used in pseudotyping 
experiments to test the functionality of individual envelope isolates. 
The second approach directly cloned patient amplicon samples in frame into HIV-1 
molecular clone pNL4-3.Luc.R
–
.E
–
 (Dr. Nathaniel Landau, the NIH AIDS Reagent Program) to 
generate replication competent viral molecular clones in a directional manner, using Gibson 
Assembly® Master Mix (New England Biolabs) according to the manufacturer’s protocol (51, 
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52). An AfeI site (AGCGCT) that does not alter the amino acid sequence was introduced at 
nucleotide 5954 of pNL4-3.Luc.R
–
.E
–
 by site directed mutagenesis. A NotI site is present in the 
vector at the 4
th
 codon of nef, the position in which the luciferase gene was inserted. The vector 
was linearized using AfeI and NotI. The insert was prepared by PCR amplification of the patient 
envelope amplicons using the following primers:  
NL4-AfeI-EnvF:  
5’-TTGTTTCATGACAAA AGCGCT AGGCATCTCCTATGGCAGGAAG -3’ 
NL4-NotI-EnvR:  
5’- TTTTGGCGTCTTCAGCGGCCGCGCCACCCATCTTATAGCAAAATCCTTTC -3’  
The PCR was performed with Q5 High-Fidelity 2× Master Mix (New England Biolabs) 
following the manufacturer’s protocol, and run on BioRad T100 thermal cycler (BioRad) using 
the following conditions: 98°C for 30 sec; 15 cycles of 98 °C for 10 sec, 55 °C for 20 sec, and 
72 °C for 2 min; and 72°C for 5 min. The PCR product included flanking regions of pNL4-
3.Luc.R
–
.E
–
. The Gibson assembly reaction was performed with an insert to vector ratio of 3:1 at 
50 °C for 60 minutes. The assembly product was diluted 1:3 and electroporated into 
ElectroMAX
TM
 Stbl4
TM
 competent cells as described above, and single clone were selected in 
the same manner for the first approach.  Colony PCR and diagnostic restriction digestion were 
performed to screen for clones containing an insert. Plasmid DNA prepared as described above 
were used in tissue-culture based phenotypic functional assays as well as genotype sequencing. 
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2.5.3 Cell Lines 
 HEK 293T cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1x 
antibacterial, antimycotic solution (containing 100 U/mL penicillin, 100 g/mL streptomycin, 
and 250 ng/mL amphotericin B). U87.CD4 cells were stably transfected with pBABE-CCR5-
GFP or pBABE-CXCR5-GFP, constructed as previously described, and maintained in DMEM 
supplemented with 15% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1x 
antibacterial, antimycotic solution, 0.2 mg/mL G418, and 1 g/mL puromycin (53).  
 
2.5.4 Virus production 
 Pseudotyped HIV-1 virions containing individual envelope variants were produced by co-
transfection of 5 g of HIV-1 molecular clone pNL4-3.Luc.R–.E– plasmid DNA and 0.5 g of 
pcDNA3.3-TOPO-CMV-Env into 4×10
5
 HEK 293T cells in a 6-well plate format using 10 L of 
TransIT®-LT1 Transfection Reagent (Mirus). Replication-competent HIV-1 containing 
individual envelope isolates were produced by transfecting 5 g of the molecular clone plasmid 
DNA as described above. The viral supernatant was harvested at 48 to 72 hours post transfection 
and passed through a 0.44 m syringe filter to remove cell debris.  
 
2.5.5 Luciferase-based infection assay 
Freshly prepared viral stocks were used to infect U87.CD4.CCR5 and U87.CD4.CXCR4 
cells in the presence of 8 g/mL DEAE dextran, as previously described (53). U87.CD4.CCR5 
and U87.CD4.CXCR4 cells were plated in 96-well plates at 10
4
 cells in 100 L of media per 
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well 24 hours before infection. During infection, 100 L of freshly harvested viral supernatant 
was added to each well in triplicates, and incubated with cells at 37 °C, 5% CO2, and 95% 
humidity for 12 hours. The virus was removed 12 hours after the start of infection, and the 
infection was continued in fresh media for another 36 hours to allow for expression of luciferase 
in the infected cells. Cells were harvested 48 hours post-infection and lysed with 0.2% Triton-
X100 (Sigma-Aldrich) in PBS. The cell lysates were read for luciferase activity on an Optocomp 
I luminometer (MGM Instruments). A result was scored as positive if the relative light unit 
readout was more than 2 standard deviations over the mean of mock infected control wells. Cells 
infected with pNL4-3.Luc.R
–
.E
–
 pseudotyped with vesicular stomatitis virus G glycoprotein 
envelope was used as the positive control, and cells infected with pNL4-3.Luc.R
–
.E
–
 alone was 
used as the negative control. 
 
2.5.6 Flow cytometry 
 The coreceptor-expressing U87-CD4 cells were stained with anti-CD4 antibody (clone 
Q4120) conjugated with phycoerythrin (Sigma-Aldrich), anti-CXCR4 antibody (clone 12G5) 
conjugated with allophycocyanin (BioLegend), and anti- CCR5 antibody (clone 2D7) conjugated 
with allophycocyanin at 4 °C in the dark for 20 minutes according to manufacturer’s protocol 
(BD Pharmingen, BD Biosciences), washed with PBS three times, resuspended in 5% FBS in 
PBS, fixed with 2% paraformaldehyde,  and  run on FACSCalibur (BD Biosciences).  Flow 
cytometry data were visualized with Flowing Software version 2.5 
(http://www.flowingsoftware.com/).   
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2.5.7 Sequence alignment and phylogenetic analysis 
Pairwise and multiple sequence alignments were performed using Needle 
(http://www.ebi.ac.uk/Tools/psa/emboss_needle/) and Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) on the European Bioinformatics Institute website. 
Phylogenetic trees of envelope variants were generated using PhyML 
(http://www.hiv.lanl.gov/content/sequence/PHYML/interface.html) or Clustal Omega with 
Pearson/FASTA output and iTOL (http://itol.embl.de/). Evolutionary analyses of specific 
envelope regions via calculating dN/dS ratio were performed using Synonymous Non-
synonymous Analysis Program (54) on the HIV database website 
(http://www.hiv.lanl.gov/content/sequence/SNAP/SNAP.html).   
 
2.5.8 Tropism prediction 
 Tropism prediction was performed using the online version of Geno2Pheno[coreceptor] 
2.5 following the developer’s instructions at http://coreceptor.geno2pheno.org/.  Only the 
Variable loop 3 (V3) region sequences were used for tropism prediction. 
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2.6 Results 
2.6.1 Evaluation of HIV-1 patient samples by single clone analysis 
HIV-1 patient samples were collected from eight study subjects at two time points on 
ACTG A5211 Phase II study of vicriviroc (VCV) (Zhang et al, manuscript). Based on the 
original phenotypic Trofile assay results, at study initiation, participants harbored viruses that 
used exclusively or preferentially CCR5 (Time point 1 at Week 0). At the second time point, 
these individuals experienced protocol-defined virologic failure, defined as less than 1 log10 
decrease of HIV-1 RNA level. At this time point, plasma env amplicons demonstrated the ability 
to utilize CXCR4 for entry, and their tropism was designated as dual-mixed (DM). The time 
elapsed between the first and second time points varied among the study subjects from 2 to 32 
weeks. 
In order to define the phenotypes of quasispecies present in these samples, we isolated 
single clones from the library of HIV-1 envelope patient amplicons and performed in-depth 
phenotypic and genotypic characterization of individual envelope-expression clones (Figure 1).  
The TOPO TA cloning technology offered an approach to clone a mixture of similar-sized 
envelope amplicon PCR products into a CMV-promoter driven expression vector and to isolate 
bacterial single colonies after transformation.  We assumed that one transformed bacterial colony 
contains a single ligated vector that contains one inserted HIV-1 env gene from the original 
patient amplicon samples. Therefore, the single colonies represent independent sampling of the 
pool of quasispecies in the original patient sample, offering a glimpse of the viral variants in the 
bloodstream of the patients at different times, during the course of VCV treatment. By sampling 
sufficient numbers of single clones, we defined the distribution of quasispecies variants, their 
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respective tropisms, and sequence similarities or differences, in order to define structure-function 
correlations of the envelope protein and its role in coreceptor specificity. 
From the sixteen samples coming from eight study subjects, we selected four samples 
from two subjects for the single clone analysis. We chose to focus on these two subjects because 
their samples demonstrated different lengths of time for coreceptor shift. Subject 1 showed high 
R5-tropic viral activity at baseline, and comparable R5- and X4-tropic activity in only two weeks. 
In contrast, samples from Subject 2 remained predominantly R5-tropic at Week 0 and Week 8, 
but also showed significantly increased X4-tropism at the second time point based on the 
luciferase assay readings in the Trofile assay (Subjects 1 and 2, Figure 4A). The difference in 
times required for coreceptor-shift might relate to distinct evolutionary pathways to switch from 
R5-tropism to dual- or X4-tropism. 
 
2.6.2 Phenotypic analysis of single clones consistent with Trofile results 
 We established a tissue-culture based luciferase-reporter infection assay that is similar to 
the bulk-screening Trofile assay. The luciferase-based infection assay consisted of producing 
pseudotyped or replication competent virions that expressed luciferase in place of Nef by 
transfecting 293T cells, and reading luciferase activity as an indicator of viral entry from infected 
U87.CD4.CCR5 or U87.CD4.CXCR4 cells (Figure 1). We generated U87.CD4 cell lines stably 
transfected and expressing CCR5-GFP or CXCR4-GFP fusion proteins on their surface (53).  
These cell lines expressed comparable levels of CD4 and coreceptor based on surface staining 
and GFP expression (Figure 2).  The activity of envelope expression clones to utilize CD4 and 
one of the two coreceptors was quantified by luciferase measurements reported as relative light 
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units (RLUs). A representative luciferase-based infection assay result is shown in Figure 3.  In 
this experiment, six out of eight clones from Sample 1.2 were functional and dual-tropic, while 
the other two clones were non-functional, defined as being unable to enter either X4- or R5-
expressing U87.CD4 cells. 
 Using the aforementioned phenotypic assay, we characterized a total of 97 single clones 
from four samples, including 6 clones from Sample 1.1, 46 clones from Sample 1.2, 10 clones 
from Sample 2.1, and 35 clones from Sample 2.2 (Figure 4B-C). The outcome was consistent 
with the Trofile assay results which examined plasma viral samples in bulk.  At the first time 
point, only R5-tropic quasispecies for Subjects 1 and 2 were found. At the second time point, 65% 
of single clones from Sample 1.2 were R5X4-tropic, and the remaining clones were non-
functional. In contrast, in Sample 2.2, 17% of clones were R5-tropic, 20% of clones were R5X4-
tropic, and 63% of clones were non-functional. . 
 
2.6.3 Quantitation of molecular cloning artifact using laboratory adapted molecular clones 
To control for mutations generated through the molecular cloning process, two lab 
adapted HIV-1 molecular clone strains p102 (pNL4.3) and p125 were processed in parallel with 
the patient amplicon samples. With the TOPO cloning approach, p102 and p125 envelope PCR 
products were ligated into pcDNA3.3-TOPO-CMV vector.  Single clones were isolated and 
tested for phenotypic functionality in the luciferase-based tropism assay, as well for genotypic 
variation via sequencing. We observed on average 12.5% of single clones being non-functional, 
and there were minimal numbers of sequence variations among the non-functional control single 
clones (Table 1). With the Gibson Assembly (GA) clone approach, we performed three sets of 
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GA ligation using envelopes from p102, p120, and 1:1 mixture of p102 and p120 as inserts. 
After quality control using colony PCR and diagnostic restriction digestion, the clones that were 
confirmed to have an insert with intact restriction sites were used in phenotypic functional testing. 
Out of all 23 clones tested from three sets combined, 3 clones were non-functional, resulting in a 
13.0% non-functional rate due to cloning artifacts (Table 1). The level of non-functional clones 
and sequence diversity observed in the controls was 3-5 folds lower comparing to the level of 
non-functional clones and sequence diversity present in the single clones isolated from patient 
amplicon samples. Therefore, the striking sequence variations observed in Sample 1.1 and 1.2 
single clones were unlikely an artifact introduced by molecular cloning, but most likely reflects 
the sequence variation in viral quasispecies present in vivo within the patients. 
 
2.6.4 Single clones within one time point were highly similar in sequence 
 To understand the structural determinants that affect coreceptor specificity, envelope 
clones were subjected to sequence analysis. Alignment of clones from Sample 1.2 by Clustal 
Omega showed a strong selection pressure towards two major variants (Figure 5). Among the six 
clones, four of them exhibited identical amino acid sequences. One of the four contained two 
synonymous mutations. Spanning the length of the partial variable loop 2 (V2) region, and the 
complete V3 and V4 regions, there were in total four positions that differed among the six clones.  
Examination of the V3 region revealed that all of six clones from Sample 1.2 bear signature of 
X4-utilization, including a glycine at the 11
th
 position, a lysine at the 25
th
 position, and overall 
positive charge of +8. Prediction of tropism, using the Geno2Pheno[coreceptor] algorithm, 
correctly identified all six clones to be X4-tropicwith a low false positive rate. Overall, the 
variants from Sample 1.2 have all been shown to be dual-tropic, and the V3 signatures were 
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consistent with functional characterization, based on previous studies. Moreover, there was a 
lack of diversity among the variable regions of the six clones from Sample 1.2, suggesting a 
strong selection pressure towards one particular genotype. These suggested that it might be 
advantageous for this virus subtype for replication in the presence of CCR5 inhibitor VCV, 
resulting in rapid change to an abundant circulating genotype within just two weeks of treatment.  
 
2.6.5 Genotypic analysis of single clones over time shows great diversity 
Longitudinal analysis of variant sequences from before and after VCV treatment of the 
same subject revealed significant quasispecies changes over time (Figure 6). Examination of the 
alignment showed that amino acid substitutions mostly concentrated in variable regions V2, V3, 
and V4.  Insertions and deletions were found exclusively in the V2 and V4 region. The 
conserved regions also contained amino acid substitutions which were located more sparsely 
than those in the variable regions. The V3 regions from samples before and after treatment 
showed sequence signatures that corresponded to R5- and X4-usage. In particular, the 25
th
 
position in the V3 region was a negatively charged glutamic acid in the R5-tropic Sample 1.1 
clone we sampled, whereas it was converted to a positively charged lysine in the X4-tropic 
Sample 1.2 clone. This observation was consistent with previous reports that the variant is more 
likely to use CXCR4 if there is at least one positively charged residue at the 11
th
 and 25
th
 
position (glycine and glutamic acid in the 1.1 clones; glycine and lysine in the 1.2 clone; 
highlighted in Figure 6) of V3. Genotypic analysis of the V3 region of these two clones 
demonstrated sequence signatures corresponding to a change of coreceptor specificity and was 
consistent with the luciferase-based phenotypic tropism assay results for these two clones, 
respectively.  
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In addition, a quantitative analysis of the alignment revealed a high level of sequence 
diversity in the V2-C3-V3-C4-V4 regions between a major clone from Sample 1.2 and one 
representative clone from Sample 1.1 (Table 1). On average, 19 – 20% of sequences were 
different in these two clones through the above mentioned regions. The variable regions showed 
over 20% of sequence differences, with the V4 region being the most variable (36 – 41% of 
sequences being different).  The conserved regions C3 and C4 were less variable as expected, 
with 13% of sequence diversity between the two clones from before and after treatment. 
Typically, the intra-clade env sequence variability was reported to be 10 – 15% among all 
circulating strains. One longitudinal study also showed that viral V3 sequences in chronically 
infected individuals stayed largely constant over time, with limited within-person evolution. 
Therefore, it was surprising to discover a much higher percentage of sequence variation in 
Subject 1 from single clones that arose over a relatively short time period of two weeks.  
 
2.6.6 Phylogenetic analysis of envelope sequences consistent with their phenotypic function 
 To dissect the evolutionary relationship between the HIV-1 env single clones, we 
generated a maximal parsimony (MP) tree using the V3 regions from the six single clones from 
Sample 1.2 and the single clone from Sample 1.1 (Figure 7).  The lab-adapted strain HXB2 that 
uses CXCR4 exclusively for entry was included as a reference. The MP tree showed clustering 
of dual-tropic clones from Sample 1.2 together on a single branch and away from the R5-tropic 
clones from Sample 1.1.  HXB2 sequence was furthest away from the patient sample clones. 
Overall, the sequence based phylogenetic analysis was consistent with the phenotypically 
validated tropism of these single clones, suggesting sequence-based analysis of envelope could 
be a valuable tool in predicting functional tropism. In addition, single clones that were close on a 
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phylogenetic tree but potentially with discordant tropisms could offer insights in important 
determinants in coreceptor shift. 
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2.7 Discussion 
 In this study, we utilized a rapid, reliable sampling method to isolate a large number of 
single clones from clinical trial subjects who developed resistance to VCV therapy. By 
performing tissue-culture based phenotypic assay and sequencing-based genotypic analysis on 
single clones, we were able to probe the viral quasispecies before and after VCV treatment in 
vivo, and understand how the HIV-1 envelope evolves in the face of a specific CCR5 antagonist 
selection. The advantage of the single clone analysis rested in the ability to fully characterize 
each individual clone and interrogate the structure-function relationship of HIV-1 envelope by 
making associations between key sequence determinants and its specific tropism status. In 
addition, the availability of the full-length envelope sequence allowed for investigation of non-
V3 determinants in the process of coreceptor shift, and phylogenetic studies looking at clones 
before and after coreceptor shift would potentially shed light on the evolutionary pathway for 
this process. 
 Single clone isolation and analysis from patient samples is an established and widely 
used approach in studying HIV-1 quasispecies. Depending on the cloning and screening 
methodology, single clone analysis with a large enough sampling size provides a survey of the 
quasispecies composition in vivo at different time points. A caveat with our approach using the 
pcDNA3.3-TOPO-CMV was a potential bias in the directional TOPO cloning strategy.  We 
observed approximately 70 – 95% of reverse-orientation insert, much higher and statistically 
significant ( p<0.01 by Chi square test), than the predicted 50% chance if the insertion 
orientation were truly random. This could potentially be due to a selection against envelope gene 
inserted in the correct orientation downstream of the CMV promoter.  A plausible speculation is 
that expression of envelope protein, even at a low level from a eukaryotic promoter, in Stbl4 
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bacterial cell leads to toxicity or cell death. There were previous reports on the leakiness of CMV 
promoter in prokaryotic systems (55). This would also result in an enrichment of non-functional 
clones that harbor premature stop codon and do not produce full-length, functional envelope 
protein. To mitigate this potential pitfall, we adopted a Gibson Assembly ligation system that 
directly cloned patient envelope amplicons into a HIV-1 molecular clone.  Since the HIV-1 LTR 
is a much weaker promoter in E. coli, the problem from toxicity of aberrantly expressed viral 
gene products should be largely alleviated if not completely eliminated. Single clones from 
Subject 2 were isolated using the latter approach.  
 In the phenotypic analysis, we observed a significant proportion of non-functional single 
clones, ranging from 50% in Sample 1.1, 35% in Sample 1.2, to 60% in Sample 2.1 and 63% in 
Sample 2.2. Given that we observed a 12.5% non-functional rate in the lab adapted p102 and 
p125 control experiments, the large percentage of non-functional single clones cannot be 
attributed to cloning artifacts alone. A plausible explanation is that these single clones are a 
natural product of viral replication. Since these patients did not have effective suppression of 
viral replication, the virus was actively replicating despite of the antiretroviral therapy. The high 
mutation rate of viral reverse transcriptase combined with a rapid viral turnover rate could 
produce numerous mutations in the progeny virus, many of these mutations being deleterious in 
nature by chance. In addition, a recent latency study showed that the viral quasispecies present in 
the peripheral blood are more likely to be defective and non-infectious in nature, comparing to 
the quasispecies in the latently infected compartment in the lymphoid organs (56). This is based 
on the observation that in chronically infected patients on HAART, there are more clonally 
expanded, dividing T cells that harbor defective provirus and release them to the circulation, in 
contrast to quiescent, non-dividing memory T cells where  the replication-competent virus 
  
71 
 
mostly reside. Therefore, the large fraction of non-functional single clones we detected is likely a 
true reflection of the viral quasispecies landscape in the plasma of the treatment-experienced 
study participants. 
 From the phenotypic and genotypic analysis of the single clones from Sample 1.1 and 1.2, 
we observed a complete shift of tropism from R5-tropic to dual-tropic clones, as well as two 
representative sequences that were, on average, 20% different. This dramatic change in tropism 
and sequences of quasispecies suggested rapid expansion of one or a several related dual-tropic 
quasispecies during the two weeks of VCV treatment. In addition, the six clones sequenced from 
Sample 1.2 were highly similar, suggesting a strong selection pressure towards this homogenous 
genotype. Overall, a phylogenetic analysis of the 1.1 and 1.2 clones showed that clones with 
similar functional tropism status were also evolutionarily closer to each other than clones with a 
different tropism. By analyzing the functions and sequences of individual clones, we were able to 
gather important information on the evolution of HIV-1 envelope quasispecies in the context of 
coreceptor inhibitor treatment.  
On the other hand, the single clones from Subject 2 showed mixed tropism even after 
VCV treatment. More detailed analysis of the 2.1 and 2.2 clones, such as dN/dS analysis on the 
full-length, variable and conserved regions of the envelope sequence, and maximal parsimony or 
neighbor joining tree analysis, are needed to understand the evolutionary relationship between 
these clones, and the potential drug-resistance mechanism of the R5-tropic clones from Sample 
2.2. A pair of evolutionarily close clones with discordant tropism status would potentially reveal 
the critical difference that leads to coreceptor shift from R5- to X4-usage.We have not been able 
to detect such a pair in the single clone analysis, likely due to the limited sample size. It is 
possible that we could detect such pairs of sequences using deep sequencing approaching. 
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Alternatively, such tropism-shift intermediate clones might not be detected at all in the patient 
plasma samples, if the viral quasispecies undergone the mutational process largely reside in 
latently infected reservoir or lymph tissues that are not sampled in this study. This is due to the 
fact that  
 One disadvantage of the single clone analysis lies in its power of this analysis, in 
particular when the number of single clones sampled is insufficient to provide an accurate 
representation of the pool of quasispecies. In this study, we analyzed a relatively large number of 
single clones from the samples of the second time point, post VCV treatment failure. 
Additionally, we performed next generation sequencing (NGS) experiments that systematically 
examined the quasispecies community (Chapter 3), which complemented and validated the 
single clone analysis. The combination of depth from the single clone analysis and breadth from 
the deep sequencing analysis provides a comprehensive understanding of envelope evolution in 
vivo and the key determinants associated with coreceptor shift. The new information of the 
structure-function relationship of HIV-1 envelope and the mechanism of coreceptor shift could 
potentially provide new prognostic tools for HIV-1 infected patients, as well as new insights 
applicable to coreceptor inhibitor design.    
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2.10 Tables   
Table 2.10.1. Summary of phenotypic and genotypic analysis for control single clones 
 
*Mutations: all the mutations observed in the non-functional full-length envelope clones. 
** p102:NL4.3 laboratory adapted strain 
***p125: NL-HXADA-GG, 2.7 kb of SalI-BamHI (5785-8474) HXADA sequence into p102 
NL4.3 backbone; HXADA comprises of BglII-BglII (7040-7620) ADA sequence into HXB2 
backbone.  
****N.D.: not determined 
  
Strains Tropism Number of Clones Non-functional Mutations* 
TOPO TA cloning with pcDNA3.3-TOPO-CMV vector 
p102** X4 12 2 5 substitutions in 2 clones 
p125*** R5 12 1 3 substitutions in 1 clone 
Gibson Assembly cloning into pNL4.3 E-R-Luc vector 
p120 X4 8 2 N.D.**** 
p125 R5 8 1 N.D. 
p102 / p125 
(1:1) 
X4 and 
R5 
7 0 N.D. 
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Table 2.10.2. Sequence comparison between one major clone from 1.2 and one clone from 1.1 
 
Regions* Length** Substitutions Diversity*** Indels
+
 
V2 through V4 272 – 279 53 19 - 19.5% 6 
V2 57 - 59 13 22 – 22.8% 2 (-4, +6) 
V3 35 8 22.9% 0 
V4 29 - 33 12 36.4 – 41.4% 3 (+1, -1, -4) 
C3 and C4 combined 151 - 152 20 13.2% 1  
 
*Regions: Variable loop 2, 3 and 4 (V2, V3 and V4) as shown in Figure 6. Conserved regions 3 
and 4 (C3 and C4) are located between V2/V3, and V3/V4 respectively. 
** Length (Lackner,  #2553): length of the specified regions in amino acid. In the case of 
insertions and deletions, the length of the particular region is shown as a range. 
***Diversity: calculated as number of amino acid substitutions divided by the length of the 
region, presented in percentage. 
+
Indels: insertions and deletions. The number of indels and their nature are presented. For 
example, in V2 region, there are 2 indels; one is a 4 amino acid deletion, the other is a 6 amino 
acid insertion.  
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2.11 Figures 
Figure 2.11.1  Schematic diagram of the experimental design. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient derived envelope quasispecies amplicons were cloned into (1) pcDNA3.3-TOPO-CMV 
expression vectors, or (2) NL4.3Env-luc+ reporter vector (plasmid libraries) and expressed in 
293T cells as (1) pseudotyped or (2) replication competent virions that were used to infect 
coreceptor expressing cell lines in the presence or absence of coreceptor inhibitors. Infected cells 
were lysed and read for luciferase activity as an indicator for infection. Approximately 50 clones 
were screened for each patient sample. The envelope genes from the single clones were also 
analyzed by Sanger sequencing.   
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Figure 2.11.2       Coreceptor-GFP cell lines express comparable levels of CD4 and 
coreceptors on the surface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (A) Unstained U87.CD4.CXCR4 (X4) and U87.CD4.CCR5 (R5) cell lines show similar level of 
GFP expression comparing to the parental U87.CD4 cell line.  
(B) X4 and R5 cell lines show comparable levels of surface CD4 staining as well as positive 
CXCR4 and CCR5 surface expression by flow cytometry comparing to unstained or negative 
controls.  Different levels of mean fluorescence intensity for CXCR4 staining on X4 cells and 
CCR5 staining on R5 cells are likely due to the inherent difference between the two conjugated 
antibodies against these surface antigens, and not a reflection of the coreceptor surface 
expression levels.     
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Figure 2.11.3    A representative luciferase-based phenotypic tropism assay for envelope 
single clones. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Out of 46 envelope single clone from Sample 1.2 tested, 8 clones are shown here.  RLU: relative 
light units.  D: dual-tropic, ability to enter using both X4 and R5 coreceptors. N.F.: non-
functional, the inability to use either X4 or R5 for entry.  Negative controls include mock 
transfection without DNA and mock infection with non-pseudotyped NL4.3-Luc Env knockout 
virus.  Positive control was NL4.3-Luc.R-.E- pseudotyped with VSV-g envelope.  Out of the 
eight clones shown in this experiment, six of them are functional and can infect both CXCR4 and 
CCR5 expressing cells.  
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Figure 2.11.4      Summary of single clone tropism analysis. 
 
 (A) Tropism analysis from bulk patient sample. Subject: HIV-1 patients who experienced 
virological failure (defined as smaller than 1 log
10
 viral load decrease at or after week 16 by 
protocol) in a Vicriviroc phase IIb clinical trial. RLU: Relative Light Units by the original 
luciferase-based Trofile assay on CCR5 (R5) or CXCR4 (X4) expressing cell lines. Tropism: the 
ability of the virus to utilize R5 and/or X4 for viral entry. DM: dual/mixed tropism. Dual 
tropism: the ability to utilize both R5 and X4 for entry; mixed tropism: coexistence of viral 
species that can use either R5 or X4 coreceptor for entry.   
(B) Single clone tropism analysis for Sample 1.1 and 1.2. (C) Single clone tropism analysis for 
Sample 2.1 and 2.2.  
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Figure 2.11.5 Variable loop region sequence analysis among 6 clones from Sample 1.2. 
 
Partial sequences of V2, complete sequences of V3 and V4 from six 1.2 clones were aligned at 
both nucleotide and amino acid level.  Four clones (2, 13, 14, and 22) are identical at amino acid 
level, though two synonymous mutations were found in clone #2.  Clone #4 and #7 contains four 
non-synonymous mutations total (annotated by asterisk * and minor variants labelled with 
squares). The 11
th
 and 25
th
 position in the V3 loop were highlighted and contain a glutamic acid 
and lysine residue respectively. 
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Figure 2.11.6      V2 through V4 region sequence analysis between a major clone from 
Sample 1.2 and a single clone from Sample 1.1. 
 
 
 
Non-synonymous mutations are annotated with asterisk (*). The 11th and 25th position in the V3 
loop were labelled by black squares. Numerous substitutions, deletions, and insertions were 
detected between the single clone from 1.1 and the major clone form 1.2 
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Figure 2.11.7      Maximal parsimony tree based on V3 sequences for six Sample 1.2 clones, 
one Sample 1.1 clone and HXB2 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
The analysis was performed with 100 iterations. Boot-strapping values are displayed next to the 
nodes between the neighboring leaves or branches. Phenotypically validated tropism was 
annotated on the side. D: dual-tropism. R5: CCR5-tropism. HXB2: a lab adapted reference strain 
that utilizes X4 for entry. The tree was built and visualized using PhyML on HIV database 
website.  
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3.1 Preface 
Chapter 3 is adapted from a manuscript submitted for publication on October 20
th
, 2015. 
The author contributions are the following: Lee Ratner and Jie Zhang conceived all the 
experiments and analysis; Jie Zhang and Xiang Gao generated all the plasmid libraries; Xiang 
Gao generated all the functional libraries; Jie Zhang and Zheng Chen developed approaches for 
sequencing data alignment, reads extraction, and entropy analysis; John Martin performed all the 
sequencing data quality control, alignment, and reads extraction. Jie Zhang analyzed all the 
processed data, and prepared all the tables and figures except for Figure 3.11.4 and Figure 3.11.5, 
which were prepared by John Martin and Bruce Rosa; Makedonka Mitreva provided intellectual 
suggestion and support for the sequencing process; Timothy Henrich
 
and Daniel Kuritzkes
 
kindly 
provided the clinical samples used in this study. The manuscript was written and revised by 
primarily by Jie Zhang and Lee Ratner; Zheng Chen, Makedonka Mitreva, and Daniel Kuritzkes 
provided useful comments. 
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3.2 Abstract 
HIV-1 envelope interacts with coreceptors CCR5 and CXCR4 in a dynamic, multi-step 
fashion. Lack of detailed understanding of the molecular mechanism of envelope-coreceptor 
interactions hampers efforts to design more effective and precise entry inhibitors. Clinical 
application of CCR5 antagonists often results in tropism shift and subsequent therapeutic failure 
in patients. Using plasma from individuals whose virus escaped a CCR5 antagonist therapy, we 
constructed libraries of replication competent proviral clones that contain full-length patient-
derived env amplicons. Tropism of quasispecies was determined by cell-based functional assays 
in vitro. Deep sequencing analysis revealed novel non-V3 region determinants that correlated 
with differential use of CCR5 and CXCR4. In particular, we identified important residues 
located on the gp120-gp41 interaction surface within one gp160 subunit, and on the gp41-gp41 
contact surface between two neighboring gp160 subunits in a trimeric spike structure. Through 
in-depth analysis of functionally validated full-length envelope sequences, this study identifies 
important structure-function relationship within HIV-1 envelope and provides mechanistic 
insight into coreceptor specificity.  
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3.3 Importance 
Preventing resistance development to current and future antiretroviral therapeutic agents 
is a top priority for global public health against HIV/AIDS. Utilizing next-generation sequencing 
approaches and phenotypic assays, we show a detailed picture of quasispecies evolution and 
treatment escape in vivo under the specific selection pressure of a CCR5 antagonist. We 
identified important regions in full-length gp160 that correlate with CXCR4 usage, in particular 
the regions at gp120-gp41 and gp41-gp41 interaction surfaces. This new line of evidence 
suggests a new hypothesis about coreceptor shift, and potentially has implications in coreceptor 
inhibitor design and tropism predictive algorithm development.  
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3.4 Introduction 
Infection by human Immunodeficiency Virus Type 1 (HIV-1) is initiated by viral 
envelope trimer binding to the host cell receptor, CD4, and subsequently one of the two 
coreceptors C-C Chemokine Receptor Type 5 (CCR5) or C-X-C Chemokine Receptor Type 4 
(CXCR4). A series of step-wise, dynamic conformational changes occurs following the two 
binding events which culminates in viral and cell membrane fusion, and release of the 
nucleocapsid core into the host cell (1, 2). The ability of a virion to bind either one or both 
chemokine receptors for entry has significant implications in disease pathogenesis, and affects 
treatment options (3). Although nearly all founder / transmitter viruses are strictly CCR5-tropic 
(termed R5 virus), close to 50% of HIV-1 subtype B patients will spontaneously develop 
CXCR4-using (X4) virus as the disease progresses, and the presence of X4 virus correlates with 
a worse clinical prognosis (4). This observation is thought to reflect the bottleneck nature of 
HIV-1 transmission, a preferential targeting of previously activated memory T lymphocytes in 
the early phase of infection, and the push to infect naïve T cells late in the disease course when 
the majority of memory T cells have been depleted (5). The process of coreceptor shift that 
otherwise naturally occurs with disease progression can take an expedited course upon the 
administration of a CCR5 antagonist antiretroviral drug (6). This limits the therapeutic 
application of CCR5 antagonists in patient management, and requires meticulous tropism 
determination prior to administration of the drug (7, 8).  
Numerous studies examined the structural aspects of HIV-1envelope and coreceptor 
interaction (9-12). There has been a continuing effort to determine the viral envelope protein 
structure in its ligand-free, mature trimer configuration, as well as in complex with neutralizing 
antibodies (13-15). Recently, high-resolution crystal structures of CCR5 and CXCR4, both in 
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complexes with a small molecular ligand, have been also determined (16, 17). These findings 
shed light on the molecular interaction between the envelope and coreceptor. However, because 
the viral entry process is highly dynamic and involves large conformational changes of a 
complex macromolecular conglomeration, there are still large gaps in our understanding at a 
molecular level. The Variable loop 3 (V3) region has been shown to play a critical role in 
coreceptor specificity, by making direct contact with the extracellular loops of CCR5 or CXCR4 
(18). Regions outside V3 have been found to affect tropism as well, but it is less clear how they 
affect the entry process (19-21).  
Currently, tropism determination approaches can be broadly categorized as phenotypic or 
genotypic approaches. Phenotypic testing, such as the Trofile assay, is primarily based on ex vivo 
determination of tropism in established coreceptor expressing cell lines, and has been the gold 
standard for tropism determination (22). Recent advances in Next-Generation Sequencing (NGS) 
technologies have made genotypic tropism testing more feasible and potentially a cheaper, faster, 
and more accurate alternative to phenotypic methods (23-27). The current challenge with the 
wide application of genotypic tropism testing lies in the ability to accurately predict tropism 
based on amino acid sequences. Current algorithms, such as Geno2Pheno and PSSM, focus 
exclusively on the V3 region sequence for tropism prediction; and the outcomes, though accurate 
for CXCR4 utilization, have a high false positive rate, and limits the application of CCR5 
antagonist drug to patients who could potentially benefit from the therapy (28-30). Therefore, it 
is important to better understand the molecular determinants for CXCR4 usage and the structure-
function relationship of HIV-1envelope, thus enhancing the predictive power of the current 
methods (20, 31). In addition, new determinants critical for CXCR4 usage can be attractive drug 
targets for development of future entry inhibitors. 
  
97 
 
Given the challenge that there are a limited number of phenotypically validated envelope 
sequences, in which most of the available sequences include only the V3 region, we devised a 
novel comprehensive approach that combines phenotypic tropism determination with NGS 
technologies, and used it to study a panel of samples from patients who failed a CCR5 inhibitor 
clinical trial. By analyzing NGS data of phenotypically validated full-length HIV-1 gp160 
sequences, we identified key determinants outside V3 that correlate with coreceptor use and 
CCR5 inhibitor resistance.  
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3.5 Materials and Methods 
3.5.1 Patient samples 
HIV-1 envelope amplicons were obtained from participants in a Vicriviroc (VCV) Phase 
II clinical trial (AIDS Clinical Trials Group [ACTG] A5211; NCT00082498) (32). Participant 
selection and sample preparation were described previously (27). Plasma samples were collected 
from study participants who experienced virologic failure and had tropism change by the 
phenotypic Trofile assay (Monogram Biosciences). Pelleted virion RNA was used to prepared 
env cDNA. Envelope amplicons were generated using previously reported primers (33):  
Env1Atopo (5’-CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-3’)  
FLenv2.2 (5’-AGCTGGATCCGTCTCGAGATACTGCTCCCACCC-3’)  
 
3.5.2 Plasmid library generation 
 Patient envelope amplicons were cloned in frame into HIV-1 molecular clone pNL4-
3.Luc.R
–
.E
–
 (Dr. Nathaniel Landau, the NIH AIDS Reagent Program) using Gibson Assembly® 
Master Mix (New England Biolabs) following the manufacturer’s protocol (34, 35). An AfeI site 
(AGCGCT) that does not alter the amino acid sequence was introduced at nucleotide 5954 of 
pNL4-3.Luc.R
–
.E
–
 by site directed mutagenesis. A NotI site is present in the vector at the 4
th
 
codon nef, the position in which the luciferase gene was inserted. The vector was linearized 
using AfeI and NotI. The insert was prepared by PCR amplification of the patient envelope 
amplicons using the following primers:  
NL4-AfeI-EnvF:  
(5’-TTGTTTCATGACAAA AGCGCT AGGCATCTCCTATGGCAGGAAG -3’)  
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NL4-NotI-EnvR:  
(5’- TTTTGGCGTCTTCAGCGGCCGCGCCACCCATCTTATAGCAAAATCCTTTC -3’).  
The PCR was set up with Q5 High-Fidelity 2× Master Mix (New England Biolabs) following 
manufacturer’s protocol, and run on BioRad T100 thermal cycler (BioRad) using the following 
conditions: 98°C for 30 sec; 15 cycles of 98°C for 10 sec, 55°C for 20 sec, and 72°C for 2 min; 
and 72°C for 5 min. The PCR product included flanking regions of pNL4-3.Luc.R
–
.E
–
. The 
Gibson assembly reaction was performed with an insert to vector ratio of 3:1 at 50 °C for 60 
minutes. The assembly product was diluted 1:3 and electroporated into ElectroMAX
TM
 Stbl4
TM
 
competent cells (Thermo Fisher) in 1 mm cuvette at 1.2 kV, 25 µF, 200 Ω mA on BioRad 
MicroPulser
TM
 (BioRad). Transformants were recovered in 1 mL of S.O.C. medium by shaking 
at 30 °C for 90 minutes at 225 RPM, and plated on Luria-Broth agar plates supplemented with 
150 g/mL of ampicillin (Sigma-Aldrich).  
 Plasmid libraries of envelope amplicons were generated by harvesting 10
6
 plate-grown 
transformant colonies and extracting plasmid DNA using QIAGEN Plasmid Plus Mega Kit 
(Qiagen). Transformed stbl4 cells were plated on 100 mm ampicillin selection plates at 10
4
 
colonies per plate. The colonies were incubated at 30 °C for 36 hours before being harvested 
using a scraper. The harvested bacterial colonies were centrifuged at 6,000 g at 4 °C for 15 
minutes in JA-14 rotor in a J2-HS centrifuge (Beckman). Endotoxin-free plasmid DNA libraries 
were prepared according to the Qiagen kit protocol. Plasmid library DNA samples for Illumina 
sequencing were prepared by restriction enzyme digestion using NotI and AfeI, followed by 
agarose gel purification of the 3 kb band corresponding to the size of the insert envelope gene. 
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3.5.3 Cell lines 
 HEK 293T cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1x 
antibacterial, antimycotic solution (containing 100 U/mL penicillin, 100 g/mL streptomycin, 
and 250 ng/mL amphotericin B). U87.CD4 cells were stably transfected with pBABE-CCR5-
GFP or pBABE-CXCR5-GFP, constructed as previously described, and maintained in DMEM 
supplemented with 15% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1x 
antibacterial, antimycotic solution, 0.2 mg/mL G418, and 1 g/mL puromycin (12).  
 
3.5.4 Virus production and passage 
 Replication-competent HIV-1 was produced in culture by transfecting 15 g of the 
molecular clone plasmid DNA into 4×10
6
 HEK 293T cells using TransIT®-LT1 Transfection 
Reagent (Mirus). The viral supernatant was harvested at 48 to 72 hours post transfection and 
passed through a 0.44 m syringe filter to remove cell debris. Freshly prepared viral stocks were 
passaged on U87.CD4.CCR5 and U87.CD4.CXCR4 cells at low multiplicity of infection (MOI 
equal to or less than 0.1), in the presence of 8 g/mL DEAE dextran, as previously described 
(12). U87.CD4.CCR5 and U87.CD4.CXCR4 cells were incubated with viral supernatant at 37 °C, 
5% CO2, and 95% humidity for 12 hours. After removing the virus and applying fresh media, 
infection proceeded for another 24 hours to allow for a single cycle of virus replication. The viral 
supernatant was then harvested from the infected U87 cells, number of infectious particles 
quantified, and virus then used in the next round of passage. 
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3.5.5 HIV-1 luciferase reporter-based titration assay 
 Viral stocks harvested from 293T or U87 cells were quantified for infectivity on 
U87.CD4.CCR5 and U87.CD4.CXCR4 cells using serial dilutions in culture media from 5 to 5
10
 
-fold (36). The diluted viral stocks were used to infect 10
4
 U87 cells in 6 replicates in a 96-well 
plate in the presence of 8 g/mL of DEAE dextran. Infection was carried out by incubating the 
cells with dilutions of viral stocks for 12 hours, removing the virus, and incubating for another 
24 hours in fresh media. Cells were harvested 24 hours post-infection and lysed with 0.2% 
Triton-X 100 (Sigma-Aldrich) in PBS. The cell lysates were read for luciferase activity on 
Optocomp I luminometer (MGM Instruments). A result was scored as positive if the relative 
light unit readout was more than 2 standard deviations over the mean of mock infected control 
wells. The number of positive and negative wells were counted, and used to compute tissue 
culture infectious units using the Spearman-Karber formula.  
 
3.5.6 Functional library DNA preparation 
 Functional libraries were prepared by PCR amplification of the envelope gene from 
integrated proviral DNA using genomic DNA of infected U87.CD4.CCR5 and 
U87.CD4.CXCR4 cells, harvested 24 hours post infection using the DNeasy Blood & Tissue 
Kits (Qiagen) according to the manufacturer’s protocol for nucleated cells. To include maximum 
number of quasispecies and to minimize PCR introduced founder effects, the entire genomic 
DNA preparation was used in multiple independent PCR runs using NL4-AfeI-EnvF and NL4-
NotI-EnvR primers, and the resultant PCR products were pooled. To minimize amplification bias 
introduced by varying template copy number, between 400-500 ng of genomic DNA was used as 
PCR template for each run, resulting in approximately 6,000 copies of proviral genome per 
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reaction, after adjusting for MOI and cell number. The final pooled PCR products were purified 
on agarose gels and quantified on TAKE3 plates using Synergy H4 Hybrid Multi-Mode 
Microplate Reader (Bio-Tek). 
 
3.5.7 Next generation sequencing (NGS)  
DNA samples were submitted to McDonnell Genome Institute at Washington University 
in St. Louis, MO for library construction and sequencing using HiSeq 2000 and/or Pacific 
Biosciences (Pac Bio) RS II. For amplicon and plasmid library sequencing with Illumina 
HiSeq2000, a minimum of 100 ng DNA per sample was used for library construction. The yield 
and size of input DNA was determined by a HS Qubit assay for quantitation (Invitrogen) and run 
on an Agilent Bioanalyzer 2100 (Agilent Technologies).  Small insert dual indexed Illumina 
paired end libraries were constructed with the KAPA LTP Library Prep kit (KAPA 
Biosystems).  100ng of genomic DNA was fragmented using the Covaris LE220 DNA Sonicator 
(Covaris) to a size range between 200-800bp using the following settings: volume = 50µL, 
temperature = 4°C, duty factor = 15%, peak incident power = 450, cycle burst = 200, time = 130 
seconds.  The Illumina ligations were amplified in eight 50uL reactions and were amplified with 
10 PCR cycles.  Libraries were fractionated on the LabChip XT using the DNA 750 chip (Perkin 
Elmer) collecting a 575bp fraction with a +/- 5% covariance, followed by an AMPure XP bead 
purification to remove residual small fragments.  Each fraction/library was assessed for 
concentration and size to determine molarity using the HS Qubit assay and the Agilent 
BioAnalyzer High Sensitivity DNA Assay. The concentration of each library fraction was 
verified through qPCR according to the manufacturer's protocol (Kapa Biosystems) to produce 
cluster counts appropriate for the Illumina HiSeq2000 platform.  The libraries were pooled in 
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equal molar ratios and loaded on 1 lane of the HiSeq2000 platform utilizing a 2x101bp recipe 
according to the manufacturer's recommendations (Illumina). 
Functional libraries of 3 kb in length were sequenced with HiSeq2000 as well as Pac Bio 
RS II. A minimum of 2 g of functional library env PCR product per sample was submitted for 
Pac Bio library construction using SMRTBell
TM
 Template Preparation Kit (Pacific Biosciences) 
following the manufacturer’s protocol. Library construction input was 750ng per library. Each 
sample was run on a single SMRT cell on the PacBio RS II platform using P6v2/C4 chemistry 
and 240 minute movie length.  
 
3.5.8 NGS data analysis  
 Illumina datasets were quality controlled by performing adaptor trimming, quality 
trimming, complexity screening, and length filtering using in-house codes. The amplicon and 
plasmid library Illumina datasets were mapped, using BWA (37) or Bowtie2 (38), to sample-
specific full-length reference sequences, which were pre-determined by Sanger-sequencing of 
single clones. Pac Bio datasets of the functional libraries were quality trimmed using the SMRT 
Portal system to extract the high-quality Reads-of-Inserts (ROIs). The ROIs were aligned to 
sample-specific references using BWA-MEM. Reads that span the entire V3 region were 
extracted and numerated, assuming every individual read represents a single DNA molecule in 
the sequencing process. Rare sequences that were occurring at single-digit read level, visibly 
different from V3 and likely arising from mapping error and frame-shift translation were 
manually removed. Single Nucleotide Polymorphism (SNP) analysis was performed using 
GATK Haplotype Caller (https://www.broadinstitute.org/gatk/).  
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3.5.9 Phylogenetic and statistical analysis 
 Hierarchical clustering was performed based on Euclidean distance matrices and 
visualized using GENE-E (http://www.broadinstitute.org/cancer/software/GENE-E/) or iTOF 
(http://itol.embl.de/). V3 loop consensus sequences from two functional clusterings and their 
significantly different amino acid positions were computed and visualized using IceLogo 
(http://iomics.ugent.be/icelogoserver/index.html). The statistical significance of the differences 
in entropy at every nucleotide position between two samples were determined by Student’s t-test. 
 
3.5.10 Deep Sequence Data Sets 
Raw sequence files from this study will be deposited in NCBI Sequence Read Archive (SRA) 
upon manuscript acceptance. Accession numbers is TBD. 
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3.6 Results  
3.6.1 Evaluation of HIV-1 patient samples by deep sequencing 
HIV-1 patient samples were collected from eight study subjects at two time points on 
ACTG A5211 Phase II study of vicriviroc (VCV) (Table 1). Based on the original Tropile in 
vitro phenotypic assay, most study participants (all but Subject 3 and 6) harbored only R5 viruses 
before VCV treatment (Time point 1 at Week 0). At the second time point where the subject 
experienced protocol-defined virologic failure (less than 1 log10 decrease of HIV-1 RNA level at 
or after Week 16), plasma env amplicons demonstrated the ability to utilize CXCR4 for entry, 
and their tropism was designated as dual-mixed (DM). The time elapsed between the first and 
second time points varied among the study subjects from 2 to 32 weeks. 
To understand HIV-1 env sequence characteristics with respect to their function, we 
devised a novel experimental scheme that allowed high-throughput phenotypic tropism 
determination followed by deep sequencing of functionally validated env libraries (Fig 1A). By 
generating a heterogeneous library of replication competent HIV-1 virions that contained a 
diverse set of env quasispecies from patient samples, we physically separated the env 
quasispecies based on their tropism by passaging the virus on CCR5- or CXCR4-expressing 
U87.CD4 cells. The subset of env variants extracted from the proviral DNA in the infected 
CCR5- or CXCR4-expressing cells was termed a functional library, and their sequences were 
determined on both Illumina and PacBio platforms. To confirm that the sequence heterogeneity 
was not lost during the process of molecular cloning, we analyzed the original patient amplicon 
samples (named amplicon libraries) and the intermediate plasmid library containing one million 
colonies using Illumina sequencing. 
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A clustering analysis using single nucleotide polymorphism (SNP) information of the 
sixteen amplicon libraries positioned the pair of samples from each study subject on a single 
branch of a Euclidean-distance tree (Fig 1B). The clustering pattern was consistent with the 
known sample identities, and confirmed that deep sequencing data can be used to accurately 
categorize HIV-1 env samples based on their sequence signatures. 
 
3.6.2 Sequence diversity of patient amplicon libraries over time 
 We first analyzed the Variable loop 3 (V3) coding sequence, as it is the primary 
determinant of coreceptor use. We found the patient samples were diverse and heterogeneous, to 
a similar degree as previous studies had reported, by counting the number and frequencies of 
different variants in the sample (24, 27). An in-depth population level variant analysis was 
performed by extracting and enumerating reads that span the entire 33 codons between the two 
cysteine residues at the beginning and the end of V3. The assumption was that one read comes 
from one DNA molecule, which comes from one quasispecies in the infected individual. Thus, 
by enumerating the non-redundant reads, we captured a snapshot of the quasispecies landscape in 
the patient at the time of sampling (27). To control for PCR introduced mutations and sequence 
errors, we performed PCR amplification and deep sequencing of a clonal control env (data not 
shown). We detected 233 distinct non-redundant variants out of 31,989 extracted V3 reads, with 
the most abundant variant that was identical to the pre-determined sequence occurring 30,967 
times (96.8%). None of the remaining 232 variants exceeded 0.05% of the total population. 
Therefore, we concluded that the error rate was low and applied a cut-off filter at 0.05% level to 
the sixteen amplicon library datasets to remove possible artifact reads. 
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 From the sixteen samples coming from eight study subjects, we selected four samples 
from two subjects (Samples 1 and 2, Table 1) for the population level variant analysis (Figure 2). 
We chose to focus on these two subjects because their samples demonstrated different lengths of 
time for coreceptor shift. Subject 1 showed high R5-tropic viral activity at baseline and 
comparable R5- and X4-tropic activity in only two weeks, whereas samples from Subject 2 
remained predominantly R5-tropic at Week 0 and Week 8, but also showed significantly 
increased X4-tropism at the second time point, based on the luciferase assay readings (Table 1). 
Examination of the variant profile revealed distinct quasispecies compositions in these two 
subjects (Figure 2A-D).  
 The viral population in Subject 1 before VCV treatment existed as one dominant variant 
that accounted for 62.6% of the total population (Figure 2A Variant 1), a less dominant variant at 
17.2% level (Figure 2A Variant 2), and numerous rare variants that occurred in single-digit 
counts and less than 1% of all V3 reads. On the other hand, the second time point sample (1.2) 
contained 2 major variants, at 46.1% and 38.8% abundance, respectively (Figure 2B Variant 1 
and 2), followed by a minor variant at 1.4% level, and rare variants at less than 1% level. 
Contrary to previous studies and our expectation that a pre-existing CXCR4-using variant at 
Week 0 expanded under drug selection to become a major variant at Week 2, we did not detect 
the major variants from Sample 1.2 (Figure 2B Variant 1 and 2) in Sample 1.1. Instead, a 
completely different and CXCR4-using population emerged and rapidly took over in two weeks, 
resulting in escape to the VCV therapy and virologic failure in Subject 1. 
 Different from Subject 1, Subject 2 showed dynamic expansion and contraction of 
variants over the 8 weeks of VCV treatment. At Week 0, the subject harbored multiple major 
variants, each at 47.6%, 20.6%, and 8.1% of the total, respectively (Figure 2C Variant 1-3), all of 
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which were predicted to use CCR5 exclusively for viral entry based on the Geno2Pheno[coreceptor] 
predictive algorithm. Some minor R5-tropic variants from Sample 2.1, present at abundances of 
5.9%, 4.7% and 1.4% (Figure 2C Variant 4-6), respectively, persisted and expanded through the 
treatment and were detected again at Week 8 at relative abundances of 15.7%, 20.9%, and 9.9% 
(Figure 2D Variant 3, 2, and 4). The most abundant variant in Sample 2.2, accounting for 25.7% 
of total reads (Figure 2D Variant 1), arose from a rare variant at 0.47% level in Sample 2.1. In 
contrast, the two most abundant variants present at 47.6% and 20.6% frequency in Sample 2.1 
were completely eliminated from the circulation. Overall, Subject 2 largely retained its 
population diversity over 8 weeks, with expansion of pre-existing CXCR4-using variants and 
maintenance of several CCR5-only variants in face of VCV treatment. 
 
3.6.3 Evaluation of plasmid and functional library variants  
 To phenotypically test a large number of env quasispecies, we generated plasmid libraries 
of complete NL4.3.Luc+ molecular clones containing env sequences from the two samples of 
Subject 1. The plasmid libraries were sequenced with Illumina HiSeq to ensure that the original 
quasispecies diversity was retained by the cloning process. We conducted the population level 
variant analysis on the plasmid library sequencing datasets and discovered almost identical 
variant distributions, with a maximal change of major variant abundance at 3.3% of the total V3 
reads (Figure 2E compared to 2A, 2F compared to 2B, and 2G).  
 Functional libraries were generated by passaging plasmid libraries 1.1 and 1.2, through 
U87.CD4.CCR5 or U87.CD4.CXCR4 cells at low MOI (≤0.1) for two or three passages each 
consisting of a single-cycle infection. A function library control was also generating by passage 
of the single env control in parallel. The four functional libraries obtained through this procedure 
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included two independent passages of Sample 1.1 on CCR5-expressing cells (thus named 
1.1_R5_FL1 and 1.1_R5_FL2), passage of Sample 1.2 on CXCR4-expressing cells (named 
1.2_X4_FL), and a control passage of the single clone isolate from Sample 1.2 on CXCR4-
expressing cells (named 1.2_Ctrl_X4). The functional libraries were sequenced by PacBio RSII 
in addition to Illumina, so that the linkage information between SNPs longer than 100 bases apart 
could be studied. 
 High-quality Reads-of-Inserts (ROIs) of the 4 functional libraries from the PacBio 
platform were generated. A total of 26,046 ROIs were obtained passed a quality filter of 99% per 
base accuracy, including 4667 ROIs from 1.1_R5_FL1, 8707 ROIs from 1.1_R5_FL2, 6783 
ROIs from 1.2_X4_FL, and 5889 ROIs from 1.2_Ctrl_X4. The average length for ROIs is 2260 
bp, with the majority of ROI at 2.9 kb, consistent with the input fragment size. All ROIs were 
generated from circular consensus sequencing of 10 passes or more, resulting in low error rate 
per base and high quality output sequencing reads.  
 Analysis of variants at population level in the four functional libraries was performed to 
understand the quasispecies profile across the envelope variable regions (Figure 3). Insufficient 
reads from the V1 region were extracted to permit meaningful analysis, likely due to the 
incompatibility between our stringent read extraction criteria and the presence of large insertion 
and deletions in this region. Therefore, we focused on the V2 through V5 regions instead. To 
control for the errors introduced by PCR, virus passaging, and sequencing procedures, we 
analyzed the clonal control 1.2_Ctrl_X4 functional library at V2 through V5, and detected 
minimal amounts of deviant variants across the five regions (data not shown). Overall, in the 
three remaining libraries, the analysis revealed distinct quasispecies landscapes for R5 versus X4 
variants. The two biological replicates, 1.1_R5_FL1 and 1.1_R5_FL2, were highly consistent in 
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terms of the major variants and their abundances across V3 – V5 regions, confirming that the 
passaging method was a reliable and reproducible approach to capture functionally validated 
quasispecies (Figure 3, Columns 1 and 2). Comparing the variant composition across the variable 
regions, the variants from V2 through V4 were more closely correlated, consistent with one 
major and one minor clone in 1.1_R5_FL1 and FL2, and two major clones in 1.2_X4_FL1. The 
V5 region appeared more variable in R5-using populations than in X4-using populations, and 
showed less correlation with the other three regions.  
 Examination of the quasispecies profiles in the V3 region of the functional libraries show 
that they were highly similar to those of the starting amplicon libraries (Figure 2A-B, Figure 3). 
The most abundant variants in Sample 1.1 and 1.2 amplicon libraries were present in the 
functional libraries, suggesting the V3 variants observed in the amplicon libraries were part of 
full-length, functional env quasispecies. The two most abundant variants in Sample 1.1 (Figure 
2A Variant 1 and 2), as well as the three most abundant variants in Sample 1.2 (Figure 2B 
Variant 1-3) were detected at comparable proportions in the functional libraries (Figure 3, Row 
2). Interestingly, a rare variant in the original amplicon library of Sample 1.1 at only 0.13% level 
(Figure 2A and B) expanded through the passaging to become the third most abundant variant in 
1.1_R5_FL1 at 3.5%, and the second most abundant variant in 1.1_R5_FL2 at 7.1% (Figure 3, 
Row 2). This suggested that the enrichment and contraction of variants in the functional library 
were not stochastic events. The ability of certain variants but not the others to persist through the 
passaging process was directly dependent on their capacity to facilitate cell entry using CD4 and 
one of the two coreceptors at a given CD4 and coreceptor concentration of the reporter cell lines.  
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3.6.4 Characterization of V3 variants based on sequence signature shows consistency with 
functional tropism 
  To dissect the sequence signature of HIV-1 env isolates and its relationship with the 
coreceptor binding function, we generated a hierarchical cluster, based on a Euclidean-distance 
matrix, using 167 V3 variants from all 4 functional libraries (Figure 4). The sequence-based 
clustering separated the variants into two groups that coincided almost perfectly with their 
function, except for three variants from CCR5 functional libraries that were grouped with 
variants from CXCR4 libraries (Figure 4, circled in green). These three variants were predicted 
by the Geno2Pheno algorithm to be able to also use CXCR4 for entry, suggesting that these were 
rare variants before treatment that could utilize CXCR4 for entry but did not expand upon VCV 
treatment likely due to low fitness. 
We generated consensus sequences of all the variants in each cluster with IceLogo2, 
taking into consideration their respectively abundance, and identified amino acid positions 
differentiating cluster 1 and cluster 2 at a significance level of P < 0.001 (Figure 5). The variants 
in CCR5 functional libraries were highly similar to each other based on the Logo plots, and were 
distinct from those in CXCR4 functional libraries. Cluster 1 showed a high degree of 
conservation, which was reflected by a major variant that accounted for over 80% of the 
population. Cluster 2 showed a clear divergence at Position 31, which was representative of two 
major variants at 43.5% and 50.2%, respectively (Figure 5A). Altogether, we identified nine 
positions (Positions 2, 20, 22, 23, 24, 25, 31, 32, and 34) in the V3 region with significantly 
different amino acid residues, that were likely responsible for the differential functionality to 
engage CCR5 versus CXCR4 as entry coreceptor (Figure 5B). Consistent with our observation, 
these positions and amino acid residues have been previously reported in HIV-1 Subtype B and 
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C patient samples to correlate with CCR5 or dual-tropism (39, 40). In addition, at the 25
th
 
position in Cluster 1 was a negatively charged glutamic acid, whereas occupying the same 
position in Cluster 2 was a positively charged lysine, which was indicative of CXCR4-usage by 
the 11/25
 
Rule (41). Through the clustering and consensus analysis, we demonstrated that 
categorizing HIV-1 V3 variants by sequence similarity created clusters that were consistent with 
their function, and confirmed that the V3 region is a critical modality for coreceptor tropism 
determination.  
 
3.6.5 Important regions outside V3 that correlate with envelope tropism 
 We analyzed the full env gene to examine other determinants of tropism beyond the V3 
region using Shannon’s entropy approach and SNP analysis. Shannon’s entropy analysis 
examines cross-sectional diversity at a given position, with higher entropy values responding to 
more diversity. We utilized entropy analysis to compare the entropy values at each nucleotide 
position between amplicon libraries of Sample 1.1 and 1.2 to explore regions that were 
undergoing an increase or decrease in diversity due to VCV selection. 
 Overall, Sample 1.1 had higher entropy across the length of the env gene than Sample 1.2, 
as demonstrated by 120 positions in Sample 1.1 and only 50 positions in Sample 1.2 that have 
statistically above-background entropy values when compared with the clonal control dataset 
(Figure 6A, p<0.0001). This suggested that the viral quasispecies population before VCV 
treatment was more heterogeneous than the quasispecies present after treatment. The treatment 
likely selected for a dominant drug-resistant variant, or a group of closely related resistant 
variants, thus, driving down the overall diversity in the population. The decrease in entropy from 
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1.1 to 1.2 occurred mostly in the V1, C2, and C5 regions, as represented by the entropy 
difference map (Figure 6B). However, specific locations showed an increase in entropy, in 
particular at HR1/HR2 regions and the cytoplasmic domain of gp41, suggesting diversifying 
selection at those loci (Table 2).  
 SNP analysis on the four functional library datasets using GATK program identified 106 
SNPs in the entire env gene with reference to the control single clone sequence from Sample 1.2. 
Clustering of the four functional library datasets based on their SNP frequency patterns reflects 
the functional categorization of the four libraries, with 1.1_R5_FL1 and 1.1_R5_FL2 on a single 
branch, and away from 1.2_X4_FL and 1.2_Ctrl_X4 on a different branch (Figure 7A). To 
identify SNPs that could differentiate CCR5 versus CXCR4 coreceptor usage, we focused on 23 
non-synonymous loci (annotated in the red boxes) that were completely different in CCR5-using 
groups than in CXCR4-using groups, including 22 loci outside the V3 region. Among the 23 
positions identified, 4 positions (N325, K421, I424, and S440) were previously known to 
strongly affect coreceptor binding and specificity, and 3 positions (N425, K432, and R476) were 
reported to be CD4 binding residues (13, 42, 43). Sixteen positions identified through the SNP 
analysis have not previously been identified to have a function in receptor or coreceptor binding, 
although many were found to be involved with gp120 – gp41 interaction (Table 2) (42-45). This 
finding suggests a role of gp120-gp41 interaction in coreceptor specificity, potentially by 
affecting entry dynamics and thus fusion efficiency following coreceptor binding. 
 For visualization of the critical regions that correlated with coreceptor specificity, 
annotation was performed on the ligand-free native envelope gp140 trimer crystal structure (PDB 
ID: 4MJZ) (Figure 7B and 7C). A group of residues (colored red) that were previously reported 
to be coreceptor-specific is located near the envelope-coreceptor binding interface and likely to 
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affect binding via direct contact with extracellular regions of the coreceptors. A second group of 
residues (colored magenta) located near the CD4 binding site are likely to affect coreceptor 
usage via interaction with CD4 and subsequent induction of a conformational change into an 
open trimer. A third group (colored blue and green) that is located at gp120-gp41 contact 
interface and the interface between the three subunits is likely to affect tropism via global 
mechanisms, such as alteration of the overall configuration of envelope trimer or its dynamic 
conformation change upon CD4 and/or coreceptor engagement. 
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3.7 Discussion 
In this study, we developed a comprehensive phenotypic assay platform in combination 
with NGS technologies to analyze HIV-1 quasispecies diversity and tropism before and after 
emergence of drug resistance in vivo. This novel approach employed a tissue-culture based 
library passaging method and allowed us to study in unprecedented depth and breadth the 
quasispecies population and their structure-function relationship by generating sequences from 
phenotypically validated env variants. The output data provided new insights into important 
features of HIV-1 env that are implicated in coreceptor interaction, and could shed light on new 
drug targets for HIV-1 entry inhibitor development. In addition, the experimental approach can 
potentially be adapted for the study of drug resistance development in other clinical situations, 
especially for development of unusual combinations of drug resistant mutations that requires 
phenotypic characterization of new and complex genotypes. 
Quality control of the sequencing data is extremely important in NGS-based studies to 
ensure the accuracy and relevance of the final conclusion. In our study, we performed all the 
experimental procedures including PCR, cloning, infection, passaging, Illumina and PacBio 
sequencing, reads filtering, and the final analysis with a clonal control of known nucleotide 
sequence in parallel. Therefore, we could calculate the cumulative error rate of PCR and cloning 
errors, passaging artifacts, and sequencing errors at every step of the process by analyzing the 
single clone control dataset and apply an appropriate filter level based on the control error rate. 
Notably, the combined error rate from PCR and sequencing in our experience were markedly 
lower than previously reported, likely reflecting improved accuracy of the higher-fidelity PCR 
polymerase and of the newer generation sequencing method (27). A potential source of error that 
we could not control for using the single clone method is strand-switching (recombination) 
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during the PCR process. Based on previously published information, the recombined clones 
accounted for equal to or less than 0.15% in the total population, and did not significantly affect 
the proportions of truly existing variants (27). In addition, we also utilized the amplicon and 
plasmid library dataset as baseline for the functional library variant analysis, and removed 
variants that did not exist in the first two libraries, therefore eliminating the majority of 
recombination errors and passaging artifacts. Biological replicates of Sample1.1 on CCR5-
expressing cell lines served as another layer of control and confirmed that our approach is robust 
and reproducible.  
The quasispecies landscape at the two snapshots through time in two study subjects 
alluded to different evolutionary pathways. Through analysis of V3 variants in amplicon libraries 
from Subject 1, we were unable to detect a minor variant at Week 0 that expanded into a major 
variant at Week 2 despite multiple rounds of sequencing and extensive depths of coverage at 
600× to 6000×. Though a minute possibility remains that the major CXCR4-using variants in 1.2 
were present in1.1 at a level too low to allow detection, a more plausible hypothesis is that the 
virus had undergone de novo mutations that conferred CXCR4-utilization, and achieved a 
complete population shift and coreceptor switch within 2 weeks. Consistent with the “fitness 
valley” model of coreceptor shift, we detected few intermediate variants from CCR5-only to 
CXCR4-using genotypes, as they are thought to be less fit and are quickly selected out (46, 47). 
On the contrary, Subject 2 demonstrated a typical dynamic quasispecies population shift under 
the selection pressure from the CCR5 antagonist, during which rare pre-existing CXCR4-using 
clones expanded and susceptible clones declined. Interestingly, several major variants predicted 
to be R5-tropic only in Sample 2.1 had unexpectedly persisted and expanded over treatment, 
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perhaps by acquiring resistance through an alternative mechanism, such as binding to the CCR5-
VCV complex for entry (6).  
One limitation of this study is the sampling method. We were unable to access 
quasispecies residing in lymph nodes and latently infected cells, as the patient samples were 
collected and prepared from free circulating virions in the plasma. Since HIV-1 quasispecies at 
these sanctuary sites are often sheltered from antiretroviral therapy, or are exposed to a lower 
dose and sub-optimal combination of antiretroviral drugs, the virus may continue to replicate at 
low levels and develop resistance progressively in a step-wise fashion, even when the treatment 
appears fully suppressive (48). Some of the viral quasispecies that eventually escape treatment 
and migrate to the blood are predicted to harbor multiple mutations, consistent with our 
observations. A recent study also shows that proviral populations in peripheral blood 
mononuclear cells are different from those in lymphoid organs and in latently infected memory 
cells; the variants in circulation are often defective or less fit (49). Since we are just beginning to 
understand these tissue-localized HIV quasispecies, more studies are needed to examine the 
evolutionary process in local lymphoid tissues and latently infected reservoirs to elucidate how 
they contribute to coreceptor shift and resistance development.  
Finally, this study has identified three regions outside V3 that strongly associate with 
coreceptor shift in the context of VCV selection, including the C4/V4/C5 region, CD4 binding 
site, and the interaction surface between gp120-gp41 and between gp41 subunits. A majority of 
the residues identified in the first two regions are consistent with and confirm previously 
published data on coreceptor specificity and viral entry. In contrast, a new subset of mutations at 
the gp120-gp41 interaction site alludes to interesting new possibilities for the mechanism of 
coreceptor shift. Since the gp120-gp41 interaction surface is located away from gp120-
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coreceptor interaction surface, mutations in this region are unlikely to directly affect gp120 
binding to coreceptor by charge or binding surface steric hindrance. They may, however, affect 
the trimer conformation and alter the affinity of envelope trimer to one coreceptor versus the 
other. These mutations may also compensate for the decrease of viral fitness from changes in 
other regions of env and promote viral entry. The new line of evidence demonstrated in this 
study contributes to our understanding of the dynamic macromolecular interactions during HIV-
1 entry, warrants further investigation via mutagenesis studies into the coreceptor shift process, 
and potentially sheds light on a new therapeutic target for entry inhibitors. 
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3.10 Tables 
Table 3.10.1 Longitudinal changes of HIV-1 envelope tropism in VCV treated patients 
 
*Subject ID Sample ID Time (weeks) R5-RLU** X4-RLU** Tropism*** 
1 
 
1.1 0 593008 86 R5 
1.2 2 139491 185312 DM 
2 
 
2.1 0 7360 129 R5 
2.2 8 6260 2034 DM 
3 
 
3.1 0 774210 388 DM**** 
3.2 24 223785 1178193 DM 
4 
 
4.1 0 434886 76 R5 
4.2 32 6627 117574 DM 
5 
 
5.1 0 37210 66 R5 
5.2 8 50461 78889 DM 
6 
 
6.1 0 511349 1920 DM 
6.2 8 124983 173363 DM 
7 
 
7.1 0 90578 63 R5 
7.2 8 8211 9836 DM 
8 
 
8.1 0 391164 73 R5 
8.2 2 1789 151040 DM 
 
* Subject: HIV-1 patients who experienced virological failure (defined as smaller than 1 log10 
viral load decrease at or after week 16 by protocol) in a Vicriviroc phase IIb clinical trial. 
** RLU: Relative Light Units by luciferase-based Trofile
®
 assay on CCR5 (R5) or CXCR4 (X4) 
expressing cell lines. 
*** Tropism: the ability of the virus to utilize R5 and/or X4 for viral entry. 
**** DM: dual/mixed tropism. Dual tropism: the ability to utilize both R5 and X4 for entry; 
mixed tropism: coexistence of viral species that can use either R5 or X4 coreceptor for entry.   
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Table 3.10.2 Positions within and outside the V3 region that correlate with coreceptor usage 
 
 
 Position
* 
SNP 
+ 
Entropy Significance Citation 
value** p value++ 
SP 24  -0.955 5.62E-05   
26  -0.901 2.99E-05  
29  0.988  2.43E-05  
C1 86 L/M   gp120-gp41 within one protomer 47 
87 E/G   gp120-gp41 interaction surface within 
single protomer; N88 glycosylation 
V1 134a  -0.956 5.73E-05   
C2 240  -0.716 1.98E-05   
256  -0.757 1.38E-05   
V3 325 D/N   Coreceptor binding site within V3 44 
327  0.988 6.62E-05 Coreceptor binding site within V3 
C3 351 E/K -0.714 6.36E-04   
V4 412 E/D     
C4 421 R/K   Coreceptor binding site outside V3 44, 13 
424 V/I   Coreceptor specific site (R5X4) 
425 N/K   CD4 contact site, main & side chain 45 
432 K/T   CD4 contact site main chain only 
440 N/S   Coreceptor binding outside V3; R5/X4  44 
442  -0.871 3.03E-05 Coreceptor binding site outside V3 
444 S/R   Cys 378 linked to Cys 445  
V5 465d R/K -0.931 8.74E-04   
C5 476 K/R   CD4 contact site, side chain only 45 
490 Q/K     
496 L/V -0.707 7.71E-05 gp120-gp41 interaction surface within 
single protomer; RRE stem I start 
46, 47 
500 K/M -0.918 4.28E-05 
503  -0.757 5.76E-05 
FP 514a M/T/I     
518 V/M     
525 T/A   gp120-gp41 interaction surface within 
single protomer 
47 
 FPPR 534 A/S   
535  -0.819 4.70E-05 gp41-gp41 interaction site & surface 
between two protomers  541 T/A   
543 R/Q   gp120-gp41 interaction surface within 
single protomer 
44, 47 
HR1 555  0.495 7.18E-04 
 596  -0.989 1.23E-05 
621 E/D -0.239 1.57E-04   
HR2 633  
0.311 9.52E-05 
gp120-gp41 interaction surface within 
single protomer 
47 
CD 724  0.983 6.38E-05   
749  0.991 2.72E-05   
802  -0.498 7.12E-05   
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* Positions are numbered based on alignment to HXB2. 
+
 Positions showing > 70% switch from reference to alternative allele in SNP analysis are 
annotated as ref/alt/alt.  Reference allele is based on 1.2 single clone control sequence. 
** Entropy value = entropy value of Sample 1.2 AL – entropy value of Sample 1.1 AL Positive 
value: increase in entropy/diversity; negative value: decrease in entropy. 
++ Positions with a significant change of entropy have p values <0.0001, by two-tailed t-test 
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3.11 Figures 
Figure 3.11.1 Experimental design and clustering of 16 samples 
 
 (A) Schematic diagram of the experimental design. Patient derived envelope quasispecies 
amplicons (amplicon libraries) were cloned into replication competent NL4.3Env-luc+ reporter 
vector (plasmid libraries) and expressed in 293T cells as replication competent virions that were 
used to infect CCR5 and CXCR4 expressing cell lines.  The functionally validated env 
quasispecies (functional libraries) were prepared by polymerase-chain reaction of the proviral 
DNA using env-specific primers from the genomic DNA of the infected cells.  The three sets of 
libraries were sequenced by Illumina HiSeq2000; functional libraries were also sequenced by 
Pacific Biosciences RS II. (B) SNP based clustering analysis of 16 amplicon libraries based on 
Illumina sequencing of the full-length env gene. SNPs were called with HXB2 env as the 
reference sequence using GATK.  A Euclidean-distance based clustering of 16 amplicon libraries 
was constructed using 843 SNPs present in all samples.    
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Figure 3.11.2 Population analysis of V3 loop sequences and frequencies in amplicon and 
plasmid libraries.   
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(A) Sample 1.1 amplicon library (AL), (B) Sample 1.2 AL, (C) Sample 2.1 AL, (D) Sample 2.2 
AL, (E) Sample 1.1 plasmid library (PL), and (F) Sample 1.2 PL. (G) A summary table 
compares amplicon libraries versus plasmid libraries for Sample 1.1 and 1.2.  Total V3 reads are 
representative of the depth of sequencing.  A clonal control env from Sample 1.2 was prepared 
and sequenced in parallel. For amplicon and plasmid libraries in (A) – (F), unique V3 variants 
and their respective frequencies are represented as slices on a pie chart. The same color in 
different libraries represents a common V3 variant found in both libraries. For amplicon libraries 
in (A) – (D), the sequences and proportions of the most abundant V3 loop variants are listed. The 
coreceptor usage predicted by Geno2Pheno[corecptor] is shown for every sequence. The 
significance level of the prediction was set at 2% and 5.75% False-Positive Rate (FPR) as the 
optimized cut-offs based on clinical data from the MOTIVATE study (FPR<0.2%: X4-capable; 
FPR>5.75%, X4-incapable.) *For the 5
th
 most abundant variant in Sample 2.2, the V3 sequence 
is predicted to be X4-capable with a FPR of 5.4%, which falls in between the optimized cut-off 
values.  
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Figure 3.11.3  Functional library population level variant analysis at env variable regions.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reads extracted from variable regions V2 (HXB2 gp160 amino acid 158 – 186d), V3 (297 – 
330), V4 (385 – 418) and V5 (460 – 469) from functional libraries 1.1_R5_FL1, 1.1_R5_FL2, 
and 1.2_X4_FL1 are visualized in pie charts with the most abundant variants annotated. 
1.1_R5_FL1 and 1.1_R5_FL2 are biological replicates prepared from Sample 1.1 passaged on 
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U87.CD4.CCR5 cells. 1.2_X4_FL1 was prepared from Sample 1.2 passaged on 
U87.CD4.CXCR4 cells.  Sequencing data shown were generated on the PacBio RS II system. 
Individual reads that span through the entire region between the given coordinates were selected, 
trimmed, and translated into amino acid sequences. Quasispecies are represented by non-
redundant amino acid sequences and are color-coded across libraries in the same row. V3 
variants are represented in same colors in Row 2 as in Figure 2A-B, and E-F.  
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Figure 3.11.4 Hierarchical clustering analysis of 167 V3 variants from four functional 
libraries (1.1_R5_FL1, 1.1_R5_FL2, 1.2_X4_FL1, and 1.2_Ctrl_X4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The presence and absence of variants is indicated using the color coded squares. Highly 
abundant variants are indicated by arrows. Green circles denote variants a, b, and c from 
1.1_R5_FL1 and/or 1.1_R5_FL2, which were grouped in Cluster 2 and predicted to use CXCR4 
by Geno2Pheno[coreceptor].   
Sequences for the three circled variants are:  
a – CTRPNNNTRKGIHIGPGRAVYVAEKIIGNIRQAHC;  
b – CIRPNNNTRKGIHIGPGRAVYVAEKIIGNIRKAYC;  
and c – CTRPNNNTRKGIHIGPGRAVYVAEKIIGNIRKAYC.    
Cluster 1 82.8% of 1.1_R5_FL1 
83.2% of 1.1_R5_FL2 
43.5% of 1.2_X4_FL1 
99.1% of 1.2_Ctrl_X4 
50.6% of 1.2_X4_FL1 
Cluster 2 
1.1_R5_FL1 
1.1_R5_FL2 
1.2_X4_FL1 
1.2_Ctrl_X4 
a 
b 
c 
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Figure 3.11.5 V3 Logo Plot for Cluster 1 and 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 (A) ConsensusV3 sequences of Cluster 1 and 2.   
(B) Significantly different amino acids (P < 0.001) between the V3 loop sequences from cluster 1 
and cluster 2. Critical residues at the 11
th
 and 25
th
 positions are highlighted with red arrows. 
 
 
 
 
 
 
  
A 
B 
  
131 
 
Figure 3.11.6 Shannon’s entropy analysis of amplicon libraries (AL) from Sample 1.1 and 
1.2. 
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 (A) Absolute entropy values at each nucleotide position along the env genes for 1.1 AL and 1.2 
AL. A total of 120 positions in Sample 1.1 (blue) and 51 positions in Sample 1.2 (red) have 
entropy values significantly over background entropy values in the 1.2 clonal control dataset (not 
shown), by one-tailed Student’s t-test, p<0.0001.   
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(B) Entropy difference at each nucleotide position along the env genes, by subtracting the values 
of 1.1 AL from that of 1.2 AL.  At 17 positions, the entropy values in Sample 1.1 differ 
significantly from those in Sample 1.2, by two-tailed Student’s t-test, p<0.0001.  
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Figure 3.11.7 Residues outside the V3 loop differentiate R5- vs. X4- usage. 
 
(A) Clustering analysis based on SNP loci allele frequency of the full-length env in four 
functional libraries. A total of 106 SNP loci were identified by GTAK using the nucleotide 
sequence of the single clone control (1.2_Ctrl_X4) as reference.  The reference allele frequency 
at each locus was calculated in every functional library and is represented as a colored block 
along the vertical axis of the plot.  Euclidean distance based matrix was used to generate the 
clustering using GENE-E. The branching over the horizontal axis represents genotype similarity 
based on similar patterns of SNPs found in all four samples. A total of 37 differentiating SNPs 
are found in the regions outline by the red boxes, among which 24 SNPs lead to non-
synonymous amino acid substitution. Only 1 out of the 24 SNPs falls within the V3 loop region. 
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(B) Representation on the gp140 SOSIP ligand-free trimer structure (PDB ID: 4ZMJ) of 21 loci 
differentiating CCR5 from CXCR4 utilization. The front view shows a trimeric spike with gp41 
on the top and gp120 at the bottom. The bottom view shows the perspective looking up from the 
host cell membrane. The subunits are shown in surface model, with gp120 in light grey and gp41 
in dark grey in two of the three protomers. The third protomer is colored by region as the 
following: light blue, gp41 ectodomain; pink, gp120; pale-yellow, V1/V2 loop; orange, V3 loop; 
and magenta, CD4 binding site (CD4bs). The differentiating loci are color-coded based on their 
known functional status previously reported in the literature.  Red: coreceptor binding or 
coreceptor specific site; magenta: CD4 contact residues; blue: intra-protomer gp120-gp41 
interaction site; green: inter-protomer gp120-gp41 and gp41-gp41 interaction site; teal: no 
previously reported function in receptor or coreceptor interaction. (C) Enlarged front and back 
views of the 21 differentiating residues on a cartoon representation of gp140 subunit.  The 
residues are annotated and grouped based on their functional status and color coded in the same 
manner as in (B).   
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Chapter 4 
Discussion and Future Directions 
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4.1 Summary 
 HIV/AIDS remains a significant public health problem worldwide. The cause of this 
problem can be attributed to the following three factors. Firstly, the lack of access to diagnostic 
testing and counselling in low- and middle-income countries with high disease burden, limited 
financial resources, and poor public health infrastructure leads to a high undiagnosed rate and 
further spread of the disease. WHO estimated that a large share of HIV-1 infection is 
undiagnosed in regions of Western Europe, Eastern Mediterranean, and Sub-Saharan Africa 
(WHO). Secondly, the lack of access to transmission prevention measures such as anti-retrovirals 
for pregnant HIV-1 positive women to block mother-to-child transmission, clean needles for 
intravenous drug users, and condoms to block sexual transmission contributes to the 2 million 
annual new infection cases. This is likely due to lack of financial resources, social stigma and 
punitive government policy (UNAIDS). Thirdly, the lack of consistent and reliable access to 
effective HAART drugs for treatment eligible individuals in low- and middle-income countries 
with high HIV/AIDS prevalence continues to bring morbidity and mortality to a 
socioeconomically disadvantaged population. The need remains to continue development of less-
toxic, more effective, new classes of antiretroviral agents, and potentially curative agents in 
pharmaceutical pipelines to battle issues with the current life-long therapy, such as hepatic and 
renal toxicity, and development and circulation of drug-resistant strains.  
One such new class of antiretroviral agent is entry inhibitors. These inhibitors work by 
blocking viral entry, the first step of the viral replication cycle. HIV entry into a host cell is a 
dynamic, multi-step process that involves viral attachment to the host cell extracellular matrix or 
receptor, viral envelope protein engagement with primary receptor CD4, recruitment and 
engagement of one of the two coreceptors CCR5 and CXCR4, followed by eventual formation of 
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the six-helix bundle and fusion pore, and translocation of viral nucleocapsid core into the host 
cell cytoplasm, as discussed in the first chapter of this dissertation. Every step in this process is 
being targeted for the development of novel entry inhibitors. Currently, two FDA-approved entry 
inhibitors include Enfuvertide (Fuzeon, Roche) that competitively blocks six-helix bundle 
formation and fusion, as well as Maraviroc (Selzentry, Pfizer) that is an allosteric inhibitor of 
CCR5 and blocks envelope-CCR5 interaction. A number of other small molecule inhibitors and 
monoclonal antibody based biologics are being developed through preclinical and clinical phases, 
among which are several coreceptor antagonists, notably CCR5 antagonists Vicriviroc (VCV) 
and TAK779, and a potent CXCR4 inhibitor AMD3100 which are not approved for HIV-1 
indication due to its side effects. During the development process and clinical application of 
some of these coreceptor inhibitors, the outgrowth of resistant strains were detected in patients 
despite tropism testing prior to treatment commencement. Multiple mechanisms were found to 
be responsible for resistance development, including a tropism change of the virus from CCR5 to 
CXCR4, and a gain in the ability of the virus to engage the CCR5-antagonist complex for entry. 
The former mechanism of coreceptor shift represents the majority of CCR5-antagonist resistant 
cases, and could be further broken down into two pathways, including (1) selective expansion of 
a minor, pre-existing CXCR4-tropic viral variant that is not detected by tropism testing, under 
the drug pressure; and (2) de novo mutations of the virus to gain the ability to utilize CXCR4 as 
its entry coreceptor. A thorough understanding of the coreceptor shift process and the route it 
takes would help with the development of more suitable clinical criteria for CCR5 antagonist 
eligibility, and with the design of more effective treatment plans in order to minimize resistance 
development and provide benefit to the largest possible population of eligible patients.  
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This study utilized a panel of patient-derived HIV-1 envelope amplicon samples before 
and after the development of VCV resistance in order to advance our understanding of the 
coreceptor shift process in vivo, as well as the basic biology of envelope-coreceptor interaction in 
general. Using a combination of single clone and next-generation sequencing (NGS) approaches 
discussed in Chapter 2 and 3, we characterized a large number of clinical isolates of HIV-1 
VCV-resistant envelope, and examined in-depth the quasispecies landscape in these patients 
before and after they became resistant to VCV treatment. We discovered drastic changes in 
envelope sequences over the course of treatment from the single clone analysis, and observed 
dynamic quasispecies population shift over the course of 2-8 weeks by NGS. With an array of 
phenotypic and genotypic assays, we analyzed a large batch of phenotypically validated 
envelope sequences, and with the Pacific Biosciences technology we were able to study 
mutations occurring along the full-length gp160 coding sequence.  We detected three regions of 
interests that strongly associate with CXCR4-usage, including but not limited to the V3 loop, 
which is the principal determinant of coreceptor specificity supported by a large body of research. 
We identified important residues that were (1) previously reported to play a role in coreceptor 
choice within and surrounding to the V3 loop; (2) reported to be CD4 contact residues, and (3) 
located on the gp120-gp41 interaction surface within one gp160 heterodimer and between the 
neighboring heterodimers within an envelope trimer spike. In addition to confirming previous 
finding that residues in the V3 loop and CD4 binding site, which make direct contact with 
coreceptor and CD4, affect coreceptor specificity, we provided new evidence that the interaction 
between gp120 and gp41, as well as the interaction between the heterodimers in an envelope 
spike, could modulate coreceptor binding. This new line of evidence leads to new hypothesis that 
the envelope protein interaction with coreceptor could be influenced possibly through more 
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global mechanisms, such as the open or closed state of envelope quaternary structure, stability of 
a particular conformational state that allows for coreceptor binding, and the affinity and duration 
of coreceptor engagement that leads to fusion and viral entry.  
Understanding of the structure-function relationship of HIV-1 envelope and the process 
of coreceptor shift is critically important, not only for the advancement in our basic scientific 
knowledge of protein-protein interaction, but also with profound clinical implications in 
development of diagnostic methods and future pharmaceutical agents. The findings from this in 
vivo study provides candidates for further in vitro causative study on envelope structure-function 
relationship, as well as potential ways to improve the current tropism predictive algorithms by 
incorporating residues with differentiating power for CXCR4-usage. It also provides new 
thoughts along the lines of modulating gp120-gp41 interaction via small molecules or 
monoclonal antibodies to restrict its quaternary structure as an approach to block entry. Last but 
not least, the knowledge of specific envelope-CXCR4 interaction sites in combination with 
known interaction sites between CXCR4 and CXCL12 could potentially lead to design of 
specific inhibitors that preferentially block envelope binding to CXCR4 but do not interfere with 
the physiological CXCR4 signaling that is essential for immune function. Further investigations 
are needed in the above mentioned areas to impact HIV/AIDS diagnosis, monitoring and 
treatment options. 
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4.2 Discussion   
 One of the major strengths of this study is that we were able to observe the viral 
quasispecies evolutionary process in vivo. The in vivo nature of study design allowed us to make 
conclusions that are based on physiological processes occurring in their natural environment. 
The patient samples were paired and contained before and after treatment samples for each study 
participant. Our assumption is that factors shaping the immune environment, including but not 
limited to cytotoxic T lymphocyte (CTL) and antibody responses, as well as the specific genetic 
makeup such as HLA, CD4, and coreceptor genotype, remained largely constant throughout the 
course of treatment; thus the major variable and driving force for coreceptor shift is the 
introduction of CCR5 antagonist into the system. The evolutionary process of coreceptor shift 
was primarily driven by VCV, with important constraints from the above-mentioned specific 
immune and genetic environment that is mostly lost in many in vitro evolutionary studies. 
Without the CTL and antibody responses and in the presence of non-physiological levels of CD4 
and coreceptor expression, the mutations detected in an in vitro drug resistance development 
setting often bear no resemblance to the ones seen in patients. In fact, over the three passages of 
viral quasispecies in the process to generate functional libraries as described in Chapter 3, we 
detected a small group of V3 variants in Sample 1.2 that lost the GPG crown motif and deviated 
significantly from the input sequences. With proper quality controls based on the quasispecies 
pool in the amplicon and plasmid libraries, we were able to manually remove these artefactual 
variants that could potentially affect downstream analysis. This highlights the necessity of 
studying the evolutionary process in a controlled, physiological setting to avoid erroneous and 
irrelevant conclusions. 
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 The flip-side of the story for an in vivo study is that it is difficult to determine causation 
in the structure-function relationship analysis. The conclusions were based on a strong 
association between certain specific residue changes and the utilization of CXCR4, yet it is 
unclear on the differentiation of key driver mutation versus auxiliary mutations. Further in vitro 
site-directed mutagenesis studies are required to understand the effect of one mutation or a 
combination of mutations on envelope-coreceptor interaction. Identifying key residues in 
multiple patients would also strongly indicate a causative role of these particular loci in 
coreceptor shift. With the availability of the remaining six patient-derived envelope amplicon 
samples, we certainly hope to continue examine the coreceptor shift process in more patients, to 
increase the power of the analysis and understand the findings in a broader context that are 
applicable to multiple patients.  
 One limitation of this study comes from the sample collection methods utilized. Since the 
patient-derived envelope amplicon samples were prepared from patient plasma, we are limited to 
exam the quasispecies population in circulation and do not have access to those variants residing 
in the peripheral lymphoid organs or the latently infected reservoirs. A recent study showed that 
the clonally expanded T cells in the circulation are more likely to harbor defective provirus 
containing deleterious mutations and large deletions than the quiescent non-dividing latently 
infected memory T cells, which usually harbor replication competent proviruses (1). This report 
is consistent with our observation that a large proportion of the single clones are non-functional, 
though molecular cloning artifact would also have a minor contribution towards the detection of 
non-functional single clones. On the other hand, previous reports have discussed the 
development of drug resistant variants in local tissues due to imperfect penetration and the 
mismatched half-lives of antiretroviral agents (2). Viral quasispecies in the local tissue may be 
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sheltered from full-strength HAART, and make slow, step-wise mutation in the context of the 
microenvironment of temporal and spatial monotherapy, only “spilling over” into the circulation 
upon achieving full drug resistance. This is consistent with our observation that the quasispecies 
population underwent a complete change of constituents over the course of treatment, and few 
drug-resistant intermediate variants were detected. This observation could be due to insufficient 
resolution and limits of detection to reveal rare, low-fitness variants in the circulation. 
Alternatively, it might be because we were looking in the wrong place, and should examine the 
quasispecies pool at the peripheral tissue instead. Future research should be conducted with the 
help of powerful NGS technologies to closely analyze viral quasispecies population in the latent 
reservoir and the peripheral tissues such as the central nervous system, in the hope to complete 
the missing pieces in the evolutionary pathway. 
 Overall, this study made a significant contribution to our knowledge of HIV-1 envelope 
structure-function relationship. The findings suggest a modular approach to understand how each 
region of the HIV-1 envelope protein, such as the V3 loop, CD4 binding site, and gp120-gp41 
interaction site, might exert an impact on envelope-coreceptor interaction and coreceptor 
specificity, through direct or indirectly mechanisms. Despite of recent progress in understanding 
the HIV-1 envelope trimer structure at different states of activation, it has been a challenge to 
understand the multimeric, dynamic interaction process of HIV entry using structural methods 
such as crystallography (3, 4). In-depth association studies using multiple patients on NGS 
platforms, biochemical and biophysical analysis of single clones, as well as site-directed 
mutagenesis studies that focus on a fine-resolution understanding of effects of single residues, 
are needed to piece together the jigsaw puzzle of the big picture of HIV envelope-coreceptor 
interaction. The information gained through thorough structure-function analysis proposed above 
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would hopefully contribute to a comprehensive model of protein interaction energy landscape, 
with which the impact of mutations and pharmaceutical interventions to enhance or disrupt the 
said interaction could be accurately simulated, thus extending our knowledge of the basic 
biology of protein-protein interaction, and guiding the development of future therapeutic agents.  
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4.3 Future work 
4.3.1 Phenotypic characterization of envelope-coreceptor interaction using biochemical, 
biophysical, and biological assays 
 In order to further our understanding of envelope sequence signature and its relationship 
with regard to tropism, more patient samples should be analyzed using a combination of the 
single clone and NGS approach. For the single clone analysis, additional work should be 
performed to fully characterize specific envelope clones that exhibit interesting coreceptor usage 
properties. Biochemical assays to analyze glycosylation levels of patient-derived clones might be 
useful in understanding how glycosylation of the envelope influences coreceptor binding and 
specificity superimposed on top of other observed mutations (5, 6). Biophysical approaches to 
accurately determine the binding affinities between envelope clones and CCR5 or CXCR4 can 
be performed using atomic force microscopy, as a previous study showed that HIV-1 envelope 
binds less strongly to CXCR4, and mutations in gp41 region that affect the formation of six-helix 
bundle might turn out to be a rate-limiting factor while the envelope is in weak association with 
CXCR4 (7). Biological assays including inhibitor IC50 analysis on the single clones or the 
quasispecies libraries might show a difference in how the VCV sensitive versus resistant 
envelopes respond to varying concentrations of coreceptor antagonists, thus probing the 
mechanism of resistance (8-10).  
 In addition, infection of chimeric coreceptor expressing U87-CD4 cell lines (NIBSC, UK) 
using patient-derived single clones and functional libraries would help dissect the interaction 
between envelope and specific regions of CCR5 and CXCR4. The three chimeric cell lines FC-1, 
FC-4b, and FC-6 were constructed so each one contains specific region of CXCR4 on a CCR5 
backbone (Figure 4.4.1). Previous studies categorized R5-tropic lab adapted and patient derived 
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single clones on these cell line into narrow-R5 and broad-R5, and showed that broad-R5 variants 
are more likely to undergo coreceptor shift to obtain the ability to use CXCR4 for entry (11-14). 
With these cell lines, we hope to define a sequence signature on HIV-1 envelope that correlates 
with its ability to utilize a particular chimeric cell line, thus deducing the key interaction domains 
on CXCR4 that is required for entry.  
 The three chimeric cell lines were quality-controlled using PCR, sequencing and flow 
cytometry. PCR using primers binding to the CCR5 amino-terminus and CXCR4 carboxyl-
terminus generated correct-sized products from the genomic DNA of FC-1, FC-4b, and FC-6, 
confirming the presence of chimeric coreceptor transgene in the genome. Sequencing of these 
PCR products confirmed the correct identity of these transgenes in the three cell lines, 
respectively. Flow cytometry of surface stained FC-1, FC-4b, and FC-6 cells using antibodies 
against CD4 (clone Q4120), CCR5 (clone 12G5) and CXCR4 (clone 2D7) showed a high level 
of cell surface expression of CD4, CCR5, and CXCR4, making these cell lines ideal for 
infectivity assays (data not shown).  
 Infection of chimeric cell lines was performed using single clones as well as functional 
libraries from Sample 1.2 passaged on X4. Interestingly, the single control clone from Sample 
1.2 that was previously determined to be dual-tropic with a preference for CXCR4 was able to 
infect FC-4b at a comparable efficiency as the CXCR4-expressing cell line, and to a lesser extent 
FC-6, but was completely non-infectious on the FC-1 cell line (Figure 4.4.2). Similarly, the 
functional library from Sample 1.2 passaged on the CXC4-expressing cell line could infect FC-
4b, and to a lesser extent, FC-6, but was unable to infect FC-1. This observation suggests that a 
combination of the CXCR4 N-terminus and CCR5 extracellular loops were counterproductive 
for dual-tropic viral entry. A single, dual-tropic envelope clone might utilize different 
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determinants to interact with CCR5 or CXCR4, and a “mixed-and-match” scenario for the two-
site interaction model did not allow viral entry. Additionally, it showed the importance of CCR5 
N-terminus for an envelope-R5 interaction, which is supported by previous studies (15, 16). 
Upon receiving the NGS dataset of FC-4b and FC-6 functional libraries of Sample 1.2 passaged 
on X4-expressing cells, analysis will be performed to understand the quasispecies that can utilize 
the two specific chimeric coreceptors, and hopefully reveal the sequence signature that allows 
them to interact with one chimeric cell line but not the other. More single clones from Subject 1 
and 2 should also be tested to differentiate narrow versus broad R5 clones, as well as narrow 
versus broad dual/X4 clones.  
 
4.3.2 Genotypic analysis of envelope-coreceptor interaction using bioinformatics tools 
 To better understand the quasispecies evolutionary process, more bioinformatics tools 
could be used to study the relationship between different envelope single clones or variants, and 
make correlation between evolution and function. In particular, dN/dS analysis could be 
performed using variants from before and after treatment, alone and combined, to reveal the 
similarity between each pair and position of every variant on a maximum likelihood 
phylogenetic tree. The input for this above-mentioned dN/dS study could be full-length gp160 
envelope sequence from single clone sequencing or Pacific Biosciences Read of Insert, or 
sequences of specific envelope regions, such as gp120, gp41, or sub-regions such as each 
individual conserved regions C1 through C5, and variable regions V1 through V5, or even using 
a sliding window format to determine the evolutionary selection on every continuous stretch of 
the envelope gene. A dN/dS value greater than 1 could indicate significant positive selection 
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pressure on the specific input region, due to a relatively weak power of this analysis on closely 
related species.   
 Another bioinformatics analysis that should be done with the existing dataset is a linkage 
analysis between different single nucleotide polymorphism (SNP) loci along the full-length 
gp160 coding sequence. Thanks to the long read length by Pacific Biosciences sequencing 
platform, it is now possible to detect positions that co-vary in X4-using or R5-using variants. A 
Viral Epidemiology Signature Pattern Analysis (VESPA) tool on HIV database website can be 
used to examine residue frequencies in the two different groups of variants, thus identifying 
sequence signature patterns associated with coreceptor specificity across the length of the 
envelope. 
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4.4 Conclusions 
 This study utilized a panel of patient-derived envelope amplicon samples to interrogate 
the evolutionary process of coreceptor shift in vivo under the specific selection pressure of a 
CCR5 antagonist therapy. Four samples from two subjects were examined in-depth to reveal 
drastic population-level shift of quasispecies from before to after CCR5 antagonist treatment. 
SNP analysis highlighted regions of interest on the envelope protein that strongly associate with 
coreceptor specificity, which includes residues near and on the V3 loop, at the CD4 binding site, 
and at the interaction surface between gp120 and gp41 within the same heterodimer and among 
neighboring heterodimers in an envelope trimeric spike. Future work should continue to perform 
phenotypic and genotypic analysis on more patient-derived samples using single clone and NGS 
approach on CCR5, CXCR4, and chimeric coreceptor expressing cell lines to (1) understand if 
the findings on two patients are broadly applicable to other patients; (2) explore structure-
function relationship in vitro with biochemical, biophysical, and biological methods; and (3) 
analyze the evolutionary relationship between quasispecies using bioinformatics approaches. The 
enhanced understanding of HIV-1 envelope interaction with host cell coreceptor CXCR4 may 
have implications in basic biology of protein-protein interaction, as well as important clinical 
implications in the diagnosis, monitoring, and treatment options for HIV/AIDS. 
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4.5 Figures 
Figure 4.5.1 Schematic diagram of CCR5, CXCR4, and the chimeric coreceptors FC-1, 
FC-4b, and FC-6. 
 
 
 
The diagram is color coded with parental constructs CXCR4 (left) in black, and CCR5 (right) in 
pink. Chimeric coreceptor constructs FC-1, FC-4b and FC-6 are colored accordingly, with 
regions from CXCR4 colored black, and regions from CCR5 colored pink. 
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Figure 4.5.2  Luciferase based infectivity assay on U87.CD4 chimeric coreceptor cell lines 
using Sample 1.2 single control clone.  
 
 
U87.CD4 is the negative control parental cell line and does not express significant levels of 
CCR5 or CXCR4. R5: U87.CD4.CCR5 cell line; X4: U87.CD4.CXCR4 cell line. A grey dotted 
line at RLU = 917 indicts the cut-off value below which is considered negative background. 
RLU: relative light unit.  
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